≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Disorders of plasma-protein metabolism, not elsewhere classified

DOID EFO Endpoint Browser PheWeb

E4_PLASMAPROT

obsolete_alpha-1-antitrypsin deficiency: ['A lung disease that is characterized as a genetic disorder caused by defective production of alpha 1-antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells. Alpha-1 antitrypsin works to protect the lungs from a naturally occuring destructive enzyme that is produced by the lungs in response to infections and toxins (such as cigarette smoke). Without enough A1AT, these enzymes slowly destroy the lung tissue causing emphysema. The symptoms include shortness of breath, wheezing, rhonchi, and rales.']

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E88.0#
  • Hospital discharge: ICD-9 — 273[8-9]
  • Cause of death: ICD-10 — E88.0#
  • Cause of death: ICD-9 — 273[8-9]

2 out of 7 registries used, show all original rules.

266

4. Check minimum number of events

None

266

5. Include endpoints

None

266

6. Filter based on genotype QC (FinnGen only)

261

Control definitions (FinnGen only)

Control exclude
E4_METABOLIA

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E88
Name in latin
Perturbationes metabolismi proteinorum plasmaticorum non alibi classificatae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1574 706 856
Only index persons 1269 601 668
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.03
Median age at first event (years)
Whole population 46.52 47.95 45.18
Only index persons 46.35 47.73 45.10

-FinnGen-

Key figures

All Female Male
Number of individuals 261 132 129
Unadjusted period prevalence (%) 0.05 0.05 0.06
Median age at first event (years) 53.95 53.44 54.47

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
266
Matched controls
2660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E88.0
ICD-10 Finland
Disorders of plasma-protein metabolism, not elsewhere classified
+∞
307.7
265
*
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
13.6
85.0
97
108
R03BB04
ATC
tiotropium bromide; inhalant
11.9
73.1
90
110
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
7.8
62.1
131
295
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
12.7
61.7
68
70
GD1AD
NOMESCO Finland
Thorax CT examination
11.5
53.9
63
70
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
14.9
45.4
43
34
J45.1
ICD-10 Finland
Nonallergic asthma
9.0
45.4
64
90
R03AK06
ATC
salmeterol and fluticasone; inhalant
6.4
43.3
94
209
J45.9
ICD-10 Finland
Asthma, unspecified
5.6
39.9
107
286
R03DA04
ATC
theophylline; systemic, rectal
10.6
38.0
45
50
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
15.4
37.2
34
25
XG410
NOMESCO Finland
Flow-volume spirometry
11.0
35.1
40
42
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.6
32.9
46
63
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
11.1
31.9
36
37
R03AK03
ATC
[U] fenoterol and ipratropium bromide
10.6
31.7
37
40
R03AK08
ATC
formoterol and beclometasone; inhalant
9.8
31.3
39
46
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
13.4
30.4
30
25
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.2
30.1
60
120
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.2
28.8
117
418
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.2
28.4
175
834
R03AC02
ATC
salbutamol; inhalant
4.9
28.1
208
1126
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.4
27.9
52
97
H02AB06
ATC
prednisolone; systemic
4.1
27.1
177
868
R03BA05
ATC
fluticasone; inhalant
4.3
26.4
92
292
127
Kela drug reimbursment
Transplant complication
37.4
26.3
33
10
J43.9
ICD-10 Finland
Emphysema, unspecified
28.6
26.0
35
14
R03DC03
ATC
montelukast; oral
4.4
25.6
83
249
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.8
25.2
43
73
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
8.8
24.8
33
42
R03AC12
ATC
salmeterol; inhalant
8.2
24.8
35
48
J45.0
ICD-10 Finland
Predominantly allergic asthma
5.5
24.7
55
121
J01MA12
ATC
levofloxacin; systemic
4.1
24.2
86
275
L04AA06
ATC
mycophenolic acid; systemic
26.7
24.1
33
14
Z94.2
ICD-10 Finland
Lung transplant status
137.4
24.0
25
*
R03BA02
ATC
budesonide; inhalant
4.1
23.2
84
271
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
68.6
22.3
25
*
R03AC03
ATC
terbutaline; inhalant
4.6
22.2
63
169
R03BA01
ATC
beclometasone; inhalant
4.4
22.1
68
194
R03AK07
ATC
formoterol and budesonide; inhalant
3.7
22.0
95
345
J47
ICD-10 Finland
Bronchiectasis
24.9
20.9
29
13
GDG10
NOMESCO Finland
Bilateral transplantation of lung
227.0
20.9
21
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.5
20.8
101
394
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.6
20.2
92
343
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
4.9
20.1
50
120
R06.0
ICD-10 Finland
Dyspnoea
3.4
20.1
103
414
R03BA08
ATC
ciclesonide; inhalant
4.8
19.2
49
120
C03CA01
ATC
furosemide; systemic
3.4
18.5
90
348
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
22.0
18.1
26
13
J43.1
ICD-10 Finland
Panlobular emphysema
+∞
17.9
17
*
E88.9
ICD-10 Finland
Metabolic disorder, unspecified
192.3
17.7
18
*
J96.1
ICD-10 Finland
Chronic respiratory failure
20.4
17.7
26
14
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
8.4
17.7
24
31
R03AC13
ATC
formoterol; inhalant
6.4
17.1
30
52
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.6
17.0
45
113
E88.8
ICD-10 Finland
Other specified metabolic disorders
+∞
16.8
16
*
TGC00
NOMESCO Finland
Bronchial lavation
7.9
16.8
24
33
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.7
16.7
65
216
C08CA02
ATC
felodipine; oral
5.5
16.4
34
69
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.6
16.0
64
216
J43.8
ICD-10 Finland
Other emphysema
64.1
16.0
18
*
L04AD01
ATC
ciclosporin; systemic
16.1
15.7
25
17
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
19.2
15.4
23
13
J45.8
ICD-10 Finland
Mixed asthma
11.9
15.4
28
26
L04AD02
ATC
tacrolimus; systemic
48.0
15.3
18
*
H02AB04
ATC
methylprednisolone; systemic
3.6
15.0
58
191
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
26.9
14.9
20
8
R03BB01
ATC
ipratropium bromide; inhalant
6.8
14.8
24
38
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
158.3
14.6
15
*
R02
ICPC
Shortness of breath/dyspnoea
3.6
14.3
55
180
C10AA03
ATC
pravastatin; oral
5.2
13.7
30
64
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
22.6
13.5
19
9
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
13.5
81
346
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
13.5
106
522
H02AB07
ATC
prednisone; oral
3.6
13.4
50
160
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.7
13.2
174
1098
J01MA14
ATC
moxifloxacin; systemic
4.0
13.1
41
116
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
3.1
13.1
67
261
WX302
NOMESCO Finland
Thoracal epidural anesthesy
5.8
13.0
25
47
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
6.2
13.0
23
40
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
21.3
12.6
18
9
R03AL06
ATC
olodaterol and tiotropium bromide; inhalant
13.3
12.4
21
17
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
6.4
12.3
21
35
G47.3
ICD-10 Finland
Sleep apnoea
2.7
12.2
88
411
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
12.2
53
187
J45
ICD-10 Finland
Asthma
3.9
12.1
39
113
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
4.5
11.7
30
73
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.6
11.6
29
69
JN3AD
NOMESCO Finland
Abdominal CT examination
3.3
11.6
49
170
C03DA01
ATC
spironolactone; oral
3.5
11.1
42
135
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.0
10.9
33
91
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.4
10.7
28
69
R5140
NOMESCO Finland
Monitoring the use of the aid
3.2
10.6
47
167
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.7
10.5
69
305
A02BC02
ATC
pantoprazole; systemic
2.5
10.5
193
1358
R06.2
ICD-10 Finland
Wheezing
4.9
10.5
24
53
UJF32
NOMESCO Finland
Coloscopy
2.5
10.4
82
396
Z50.1
ICD-10 Finland
Other physical therapy
4.8
10.2
24
54
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.8
10.2
24
54
J46
ICD-10 Finland
Status asthmaticus
9.3
10.0
20
23
R28
ICPC
Limited function/disability (R)
27.2
9.9
13
5
R06AE07
ATC
cetirizine; oral
2.3
9.8
135
830
J01AA02
ATC
doxycycline; systemic
2.8
9.7
218
1652
SPAT1254
SPAT
Administration of medicine
3.0
9.6
46
171
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
4.3
9.6
26
66
J93.1
ICD-10 Finland
Other spontaneous pneumothorax
+∞
9.4
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
9.2
66
303
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.0
9.1
27
73
R03AL08
ATC
vilanterol, umeclidinium bromide and fluticasone furoate; inhalant
10.0
8.9
17
18
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.4
8.8
33
105
R96
ICPC
Asthma
3.3
8.7
36
122
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
8.7
8.7
18
22
ZX108
NOMESCO Finland
Inhalation
20.8
8.5
12
6
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.7
8.5
20
45
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.8
8.5
48
195
R05CB01
ATC
acetylcysteine; inhalant, oral
13.4
8.5
14
11
XX4BW, ,
NOMESCO Finland
92.9
8.5
9
*
TPH07
NOMESCO Finland
Cathetrisation of artery
3.1
8.4
37
131
R81
ICPC
Pneumonia
5.0
8.2
18
38
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
34.5
8.1
10
*
J43.2
ICD-10 Finland
Centrilobular emphysema
34.5
8.1
10
*
I50.9
ICD-10 Finland
Heart failure, unspecified
3.2
8.1
35
122
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
22.8
8.1
11
5
WX872
NOMESCO Finland
Intensive care
4.2
8.1
22
56
WW200
NOMESCO Finland
Immunization
7.0
8.0
19
29
J01FA10
ATC
azithromycin; systemic
2.1
8.0
170
1204
R95
ICPC
Chron obstructive pulmonary disease
6.7
7.9
19
30
R01AD09
ATC
mometasone; nasal
2.1
7.9
136
891
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.4
7.8
29
92
M05BA04
ATC
alendronic acid; oral
3.6
7.8
27
82
Z31.5
ICD-10 Finland
Genetic counselling
3.6
7.7
26
77
XG466
NOMESCO Finland
Sleep oxymetry
7.1
7.7
18
27
XG474
NOMESCO Finland
Exhalation nntrogen oxide
7.1
7.7
18
27
Z94.4
ICD-10 Finland
Liver transplant status
82.3
7.5
8
*
A02BC05
ATC
esomeprazole; systemic
2.0
7.4
116
729
2776A
ICD-9 Finland
Other and unspecified disorders of metabolism, Other deficiencies of circulating enzymes[DEFECTUS ALFA1-ANTITRYPSINI]
+∞
7.3
7
*
JJC00
NOMESCO Finland
Allogenic transplantation of liver
+∞
7.3
7
*
A07AA02
ATC
nystatin; oral
3.8
7.3
23
65
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
7.7
7.3
16
22
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
3.3
7.3
29
96
JN1BG
NOMESCO Finland
MRI examination of upper part of abodmen with high intensity magnet
16.3
7.3
11
7
ZX109
NOMESCO Finland
Instruction on medicine inhalation technique
16.3
7.3
11
7
PD4DE
NOMESCO Finland
Lower extremity artery ultrasound examination with Doppler method
16.3
7.3
11
7
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.4
7.3
58
278
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
30.9
7.2
9
*
R4190
NOMESCO Finland
Nutritional therapy
4.4
7.1
18
43
M05BX04
ATC
denosumab; parenteral
4.1
7.1
20
52
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
7.9
7.0
15
20
R07.4
ICD-10 Finland
Chest pain, unspecified
2.1
6.9
77
424
R04.2
ICD-10 Finland
Haemoptysis
6.0
6.9
18
32
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
3.4
6.9
25
78
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
17.2
6.8
10
6
5AB14, ,
NOMESCO Finland
41.1
6.8
8
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
6.8
45
198
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
6.7
103
637
C09AA05
ATC
ramipril; oral
2.2
6.7
66
346
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.5
6.6
47
213
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
6.0
6.6
17
30
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.0
6.6
116
753
C07AB07
ATC
bisoprolol; oral
1.9
6.4
117
766
J01MA02
ATC
ciprofloxacin; systemic
2.0
6.4
104
655
R06AX26
ATC
fexofenadine; oral
3.2
6.3
26
88
GD1RA
NOMESCO Finland
Dynamic X-ray examination of respiratory organs with convetional X-ray picture
+∞
6.3
6
*
R03BC03
ATC
nedocromil; inhalant
3.1
6.3
27
94
R50.9
ICD-10 Finland
Fever, unspecified
2.4
6.2
47
219
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
3.9
6.2
18
48
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
2.6
6.1
38
161
AN1
HP
Coronary angiography
3.2
6.1
24
79
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.9
6.0
18
49

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pulmonary Disease
29 [38004472]
2.1e+00
2.9e+00
3.0e+00
1.0e+50
3.6e+00
3.4e+00
3.1e+00
cases:35.36%
controls:6.02%
cases:39.54%
controls:3.55%
cases:13.31%
controls:0.72%
cases:63.50%
controls:0.00%
cases:18.99%
controls:0.61%
cases:51.79%
controls:3.33%
cases:63.36%
controls:7.51%
93
158
170
2465
104
93
159
2530
35
19
228
2604
167
0
96
2623
49
16
209
2607
130
86
121
2496
147
176
85
2169
tiotropium bromide; inhalant
R03BB04 [21603296]
2.4e+00
2.8e+00
2.8e+00
—
3.1e+00
2.8e+00
2.9e+00
cases:12.93%
controls:1.33%
cases:13.69%
controls:0.95%
cases:4.94%
controls:0.30%
—
—
cases:6.20%
controls:0.30%
cases:14.34%
controls:1.01%
cases:22.41%
controls:1.62%
34
35
229
2588
36
25
227
2598
13
8
250
2615
—
16
8
242
2615
36
26
215
2556
52
38
180
2307
Outpatient Visit
OP [9202]
7.7e-01
1.2e+00
9.7e-01
6.5e+00
1.6e+00
1.6e+00
1.8e+00
cases:79.85%
controls:64.70%
cases:72.24%
controls:43.50%
cases:21.67%
controls:9.53%
cases:61.22%
controls:0.23%
cases:31.01%
controls:8.27%
cases:78.49%
controls:41.87%
cases:94.83%
controls:74.58%
210
1697
53
926
190
1141
73
1482
57
250
206
2373
161
6
102
2617
80
217
178
2406
197
1081
54
1501
220
1749
12
596
FEV1/FVC
19926-5 [3011505]
2.4e+00
3.2e+00
1.0e+50
1.0e+50
—
3.9e+00
3.5e+00
cases:10.27%
controls:1.07%
cases:7.98%
controls:0.34%
cases:4.56%
controls:0.00%
cases:6.46%
controls:0.00%
—
—
cases:10.76%
controls:0.23%
cases:20.69%
controls:0.77%
27
28
236
2595
21
9
242
2614
12
0
251
2623
17
0
246
2623
—
27
6
224
2576
48
18
184
2327
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
2.4e+00
3.2e+00
1.0e+50
1.0e+50
—
3.9e+00
3.5e+00
cases:10.27%
controls:1.07%
cases:7.98%
controls:0.34%
cases:4.56%
controls:0.00%
cases:6.46%
controls:0.00%
—
—
cases:10.76%
controls:0.23%
cases:20.69%
controls:0.77%
27
28
236
2595
21
9
242
2614
12
0
251
2623
17
0
246
2623
—
27
6
224
2576
48
18
184
2327
FEV1
20150-9 [3024653]
2.4e+00
3.2e+00
1.0e+50
1.0e+50
—
3.9e+00
3.5e+00
cases:10.27%
controls:1.07%
cases:7.98%
controls:0.34%
cases:4.56%
controls:0.00%
cases:6.46%
controls:0.00%
—
—
cases:10.76%
controls:0.23%
cases:20.69%
controls:0.77%
27
28
236
2595
21
9
242
2614
12
0
251
2623
17
0
246
2623
—
27
6
224
2576
48
18
184
2327
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
2.8e+00
3.2e+00
—
1.0e+50
—
3.4e+00
3.2e+00
cases:12.55%
controls:0.84%
cases:16.35%
controls:0.76%
—
—
cases:17.11%
controls:0.00%
—
—
cases:17.93%
controls:0.70%
cases:24.14%
controls:1.28%
33
22
230
2601
43
20
220
2603
—
45
0
218
2623
—
45
18
206
2564
56
30
176
2315
FVC percent change Respiratory system
69982-7 [42868471]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.7e+00
3.4e+00
cases:8.37%
controls:0.91%
cases:6.46%
controls:0.30%
cases:3.80%
controls:0.00%
cases:4.18%
controls:0.00%
—
—
cases:7.57%
controls:0.19%
cases:16.38%
controls:0.64%
22
24
241
2599
17
8
246
2615
10
0
253
2623
11
0
252
2623
—
19
5
232
2577
38
15
194
2330
FEV1/FVC --post bronchodilation
69970-2 [42868459]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.7e+00
3.4e+00
cases:8.37%
controls:0.91%
cases:6.46%
controls:0.30%
cases:3.80%
controls:0.00%
cases:4.18%
controls:0.00%
—
—
cases:7.57%
controls:0.19%
cases:16.38%
controls:0.64%
22
24
241
2599
17
8
246
2615
10
0
253
2623
11
0
252
2623
—
19
5
232
2577
38
15
194
2330
FEV1 percent change
69983-5 [42868472]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.7e+00
3.4e+00
cases:8.37%
controls:0.91%
cases:6.46%
controls:0.30%
cases:3.80%
controls:0.00%
cases:4.18%
controls:0.00%
—
—
cases:7.57%
controls:0.19%
cases:16.38%
controls:0.64%
22
24
241
2599
17
8
246
2615
10
0
253
2623
11
0
252
2623
—
19
5
232
2577
38
15
194
2330
FEV1 --post bronchodilation
20155-8 [3023550]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.7e+00
3.4e+00
cases:8.37%
controls:0.91%
cases:6.46%
controls:0.30%
cases:3.80%
controls:0.00%
cases:4.18%
controls:0.00%
—
—
cases:7.57%
controls:0.19%
cases:16.38%
controls:0.64%
22
24
241
2599
17
8
246
2615
10
0
253
2623
11
0
252
2623
—
19
5
232
2577
38
15
194
2330
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
2.3e+00
3.1e+00
1.0e+50
1.0e+50
—
3.7e+00
3.4e+00
cases:8.37%
controls:0.91%
cases:6.46%
controls:0.30%
cases:3.80%
controls:0.00%
cases:4.18%
controls:0.00%
—
—
cases:7.57%
controls:0.19%
cases:16.38%
controls:0.64%
22
24
241
2599
17
8
246
2615
10
0
253
2623
11
0
252
2623
—
19
5
232
2577
38
15
194
2330
Gastroenterology
10 [38004455]
1.2e+00
1.9e+00
2.6e+00
1.0e+50
2.6e+00
2.3e+00
1.6e+00
cases:13.31%
controls:4.61%
cases:13.31%
controls:2.21%
cases:5.32%
controls:0.42%
cases:9.51%
controls:0.00%
cases:5.43%
controls:0.42%
cases:16.33%
controls:1.86%
cases:19.40%
controls:4.82%
35
121
228
2502
35
58
228
2565
14
11
249
2612
25
0
238
2623
14
11
244
2612
41
48
210
2534
45
113
187
2232
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
3.0e+00
3.1e+00
—
—
—
3.0e+00
2.7e+00
cases:5.70%
controls:0.30%
cases:4.94%
controls:0.23%
—
—
—
—
—
—
cases:4.38%
controls:0.23%
cases:5.60%
controls:0.38%
15
8
248
2615
13
6
250
2617
—
—
—
11
6
240
2576
13
9
219
2336
salmeterol and fluticasone
R03AK06 [21603280]
2.0e+00
2.2e+00
1.9e+00
—
1.8e+00
2.1e+00
1.9e+00
cases:15.21%
controls:2.48%
cases:14.83%
controls:1.98%
cases:3.42%
controls:0.53%
—
—
cases:4.26%
controls:0.76%
cases:13.55%
controls:1.86%
cases:18.53%
controls:3.28%
40
65
223
2558
39
52
224
2571
9
14
254
2609
—
11
20
247
2603
34
48
217
2534
43
77
189
2268
formoterol and beclometasone
R03AK08 [43534839]
2.1e+00
2.3e+00
—
—
2.5e+00
2.2e+00
2.6e+00
cases:3.80%
controls:0.50%
cases:3.42%
controls:0.34%
—
—
—
—
cases:2.33%
controls:0.19%
cases:4.38%
controls:0.50%
cases:11.64%
controls:0.94%
10
13
253
2610
9
9
254
2614
—
—
6
5
252
2618
11
13
240
2569
27
22
205
2323
Nonallergic asthma
J45.1 [45557625]
2.6e+00
2.8e+00
—
1.0e+50
—
3.4e+00
2.8e+00
cases:8.75%
controls:0.69%
cases:7.22%
controls:0.46%
—
—
cases:7.22%
controls:0.00%
—
—
cases:9.16%
controls:0.35%
cases:13.36%
controls:0.94%
23
18
240
2605
19
12
244
2611
—
19
0
244
2623
—
23
9
228
2573
31
22
201
2323
Pharmacy visit
OMOP4822462 [581458]
1.4e+00
1.8e+00
8.0e-01
2.0e+00
1.1e+00
1.9e+00
2.5e+00
cases:98.10%
controls:92.91%
cases:96.20%
controls:80.63%
cases:58.94%
controls:39.19%
cases:12.55%
controls:1.87%
cases:65.12%
controls:38.62%
cases:96.81%
controls:82.30%
cases:99.57%
controls:94.75%
258
2437
5
186
253
2115
10
508
155
1028
108
1595
33
49
230
2574
168
1013
90
1610
243
2125
8
457
231
2222
1
123
prednisolone; oral, parenteral
H02AB06 [21602734]
1.3e+00
1.8e+00
1.7e+00
—
2.2e+00
1.8e+00
1.8e+00
cases:25.86%
controls:9.04%
cases:17.87%
controls:3.39%
cases:3.42%
controls:0.65%
—
—
cases:3.49%
controls:0.38%
cases:19.12%
controls:3.91%
cases:40.09%
controls:9.77%
68
237
195
2386
47
89
216
2534
9
17
254
2606
—
9
10
249
2613
48
101
203
2481
93
229
139
2116
prednisolone
A07EA01 [21600653]
1.3e+00
1.8e+00
1.7e+00
—
2.2e+00
1.8e+00
1.8e+00
cases:25.86%
controls:9.07%
cases:17.87%
controls:3.39%
cases:3.42%
controls:0.65%
—
—
cases:3.49%
controls:0.38%
cases:19.12%
controls:3.91%
cases:40.09%
controls:9.77%
68
238
195
2385
47
89
216
2534
9
17
254
2606
—
9
10
249
2613
48
101
203
2481
93
229
139
2116
Supplier / Service Provider
OMOP5117446 [33004]
-4.1e-01
4.5e-01
2.1e+00
1.0e+50
—
4.3e+00
4.1e+00
cases:19.77%
controls:27.03%
cases:12.55%
controls:8.35%
cases:6.08%
controls:0.80%
cases:6.46%
controls:0.00%
—
—
cases:14.34%
controls:0.23%
cases:31.47%
controls:0.77%
52
709
211
1914
33
219
230
2404
16
21
247
2602
17
0
246
2623
—
36
6
215
2576
73
18
159
2327
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
2.1e+00
2.9e+00
1.0e+50
1.0e+50
—
3.2e+00
2.0e+00
cases:7.60%
controls:0.99%
cases:7.22%
controls:0.42%
cases:2.28%
controls:0.00%
cases:3.42%
controls:0.00%
—
—
cases:5.58%
controls:0.23%
cases:14.66%
controls:2.30%
20
26
243
2597
19
11
244
2612
6
0
257
2623
9
0
254
2623
—
14
6
237
2576
34
54
198
2291
Office Visit
OMOP4822458 [581477]
6.8e-01
1.3e+00
2.2e+00
1.0e+50
2.7e+00
1.9e+00
1.3e+00
cases:12.55%
controls:6.79%
cases:9.13%
controls:2.55%
cases:2.28%
controls:0.27%
cases:1.90%
controls:0.00%
cases:2.71%
controls:0.19%
cases:10.76%
controls:1.82%
cases:19.40%
controls:5.88%
33
178
230
2445
24
67
239
2556
6
7
257
2616
5
0
258
2623
7
5
251
2618
27
47
224
2535
45
138
187
2207
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.0e-01
1.3e+00
3.2e+00
—
2.5e+00
1.6e+00
1.2e+00
cases:11.41%
controls:6.02%
cases:12.55%
controls:3.85%
cases:7.22%
controls:0.30%
—
—
cases:5.04%
controls:0.42%
cases:13.15%
controls:2.98%
cases:22.41%
controls:8.14%
30
158
233
2465
33
101
230
2522
19
8
244
2615
—
13
11
245
2612
33
77
218
2505
52
191
180
2154
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.6e-01
1.2e+00
2.8e+00
—
2.1e+00
1.5e+00
1.4e+00
cases:11.79%
controls:5.38%
cases:9.89%
controls:3.24%
cases:8.37%
controls:0.57%
—
—
cases:3.49%
controls:0.46%
cases:11.95%
controls:3.02%
cases:21.98%
controls:6.57%
31
141
232
2482
26
85
237
2538
22
15
241
2608
—
9
12
249
2611
30
78
221
2504
51
154
181
2191
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
6.3e-01
1.3e+00
2.9e+00
1.0e+50
2.3e+00
1.6e+00
1.4e+00
cases:12.55%
controls:7.13%
cases:15.59%
controls:4.61%
cases:11.41%
controls:0.72%
cases:2.28%
controls:0.00%
cases:6.98%
controls:0.72%
cases:16.73%
controls:4.07%
cases:31.90%
controls:10.32%
33
187
230
2436
41
121
222
2502
30
19
233
2604
6
0
257
2623
18
19
240
2604
42
105
209
2477
74
242
158
2103
formoterol; inhalant
R03AC13 [21603267]
1.7e+00
2.6e+00
—
—
—
2.6e+00
2.6e+00
cases:3.42%
controls:0.65%
cases:3.42%
controls:0.27%
—
—
—
—
—
—
cases:3.59%
controls:0.27%
cases:4.74%
controls:0.38%
9
17
254
2606
9
7
254
2616
—
—
—
9
7
242
2575
11
9
221
2336
Predominantly allergic asthma
J45.0 [45557624]
2.2e+00
2.5e+00
—
1.0e+50
—
2.4e+00
2.3e+00
cases:7.22%
controls:0.88%
cases:4.94%
controls:0.42%
—
—
cases:2.66%
controls:0.00%
—
—
cases:3.98%
controls:0.39%
cases:8.62%
controls:0.98%
19
23
244
2600
13
11
250
2612
—
7
0
256
2623
—
10
10
241
2572
20
23
212
2322
Asthma, unspecified
J45.9 [45562456]
1.8e+00
2.3e+00
—
1.0e+50
—
2.5e+00
2.3e+00
cases:12.17%
controls:2.33%
cases:10.65%
controls:1.18%
—
—
cases:12.55%
controls:0.00%
—
—
cases:12.75%
controls:1.16%
cases:21.55%
controls:2.60%
32
61
231
2562
28
31
235
2592
—
33
0
230
2623
—
32
30
219
2552
50
61
182
2284
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.9e-01
1.1e+00
2.6e+00
—
2.0e+00
1.3e+00
1.1e+00
cases:16.35%
controls:8.12%
cases:13.31%
controls:4.77%
cases:9.89%
controls:0.84%
—
—
cases:4.26%
controls:0.57%
cases:14.34%
controls:4.57%
cases:25.86%
controls:10.58%
43
213
220
2410
35
125
228
2498
26
22
237
2601
—
11
15
247
2608
36
118
215
2464
60
248
172
2097
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
1.9e+00
2.3e+00
1.0e+50
—
—
2.6e+00
1.9e+00
cases:5.32%
controls:0.80%
cases:3.04%
controls:0.30%
cases:4.18%
controls:0.00%
—
—
—
—
cases:3.59%
controls:0.27%
cases:6.47%
controls:0.98%
14
21
249
2602
8
8
255
2615
11
0
252
2623
—
—
9
7
242
2575
15
23
217
2322
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.7e-01
1.1e+00
2.6e+00
—
2.0e+00
1.3e+00
1.0e+00
cases:15.97%
controls:8.12%
cases:13.31%
controls:4.80%
cases:9.89%
controls:0.84%
—
—
cases:4.26%
controls:0.61%
cases:14.34%
controls:4.57%
cases:25.43%
controls:10.70%
42
213
221
2410
35
126
228
2497
26
22
237
2601
—
11
16
247
2607
36
118
215
2464
59
251
173
2094
budesonide; inhalant
R03BA02 [21603285]
1.4e+00
1.9e+00
1.4e+00
—
2.3e+00
1.7e+00
1.4e+00
cases:15.59%
controls:4.46%
cases:14.45%
controls:2.44%
cases:1.90%
controls:0.46%
—
—
cases:5.43%
controls:0.57%
cases:13.55%
controls:2.83%
cases:17.67%
controls:4.82%
41
117
222
2506
38
64
225
2559
5
12
258
2611
—
14
15
244
2608
34
73
217
2509
41
113
191
2232
fenoterol and ipratropium bromide
R03AL01 [43534843]
3.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:7.22%
controls:0.27%
—
—
—
—
—
—
—
—
cases:3.19%
controls:0.23%
cases:6.47%
controls:0.47%
19
7
244
2616
—
—
—
—
8
6
243
2576
15
11
217
2334
Basophils/Leukocytes in Blood
30180-4 [3022096]
7.8e-01
1.1e+00
2.6e+00
—
1.9e+00
1.3e+00
1.0e+00
cases:15.97%
controls:8.04%
cases:13.31%
controls:4.84%
cases:9.89%
controls:0.84%
—
—
cases:4.26%
controls:0.65%
cases:14.34%
controls:4.57%
cases:25.43%
controls:10.79%
42
211
221
2412
35
127
228
2496
26
22
237
2601
—
11
17
247
2606
36
118
215
2464
59
253
173
2092
salbutamol; inhalant
R03AC02 [21603256]
1.3e+00
2.0e+00
9.3e-01
1.0e+50
2.0e+00
1.6e+00
1.7e+00
cases:35.36%
controls:13.15%
cases:31.94%
controls:6.18%
cases:3.42%
controls:1.37%
cases:2.28%
controls:0.00%
cases:7.36%
controls:1.03%
cases:27.49%
controls:6.86%
cases:49.14%
controls:14.97%
93
345
170
2278
84
162
179
2461
9
36
254
2587
6
0
257
2623
19
27
239
2596
69
177
182
2405
114
351
118
1994
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
1.9e+00
2.4e+00
—
—
—
2.5e+00
1.8e+00
cases:8.75%
controls:1.41%
cases:3.80%
controls:0.34%
—
—
—
—
—
—
cases:4.38%
controls:0.39%
cases:6.90%
controls:1.19%
23
37
240
2586
10
9
253
2614
—
—
—
11
10
240
2572
16
28
216
2317
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
7.5e-01
1.1e+00
2.4e+00
—
2.0e+00
1.2e+00
1.1e+00
cases:16.35%
controls:8.46%
cases:13.31%
controls:4.99%
cases:9.13%
controls:0.88%
—
—
cases:4.26%
controls:0.61%
cases:14.34%
controls:4.73%
cases:26.72%
controls:11.04%
43
222
220
2401
35
131
228
2492
24
23
239
2600
—
11
16
247
2607
36
122
215
2460
62
259
170
2086
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
7.4e-01
9.5e-01
2.4e+00
—
2.0e+00
1.2e+00
1.1e+00
cases:15.97%
controls:8.31%
cases:11.79%
controls:4.92%
cases:8.75%
controls:0.84%
—
—
cases:4.26%
controls:0.57%
cases:13.55%
controls:4.65%
cases:26.72%
controls:10.79%
42
218
221
2405
31
129
232
2494
23
22
240
2601
—
11
15
247
2608
34
120
217
2462
62
253
170
2092
Internal Medicine
11 [38004456]
8.8e-01
1.3e+00
2.0e+00
—
1.6e+00
1.3e+00
1.3e+00
cases:31.94%
controls:16.32%
cases:19.77%
controls:6.21%
cases:5.70%
controls:0.84%
—
—
cases:5.43%
controls:1.11%
cases:19.12%
controls:5.93%
cases:37.50%
controls:14.07%
84
428
179
2195
52
163
211
2460
15
22
248
2601
—
14
29
244
2594
48
153
203
2429
87
330
145
2015
ciclesonide; inhalant
R03BA08 [21603291]
1.5e+00
2.6e+00
—
—
—
2.5e+00
1.8e+00
cases:4.56%
controls:1.07%
cases:5.32%
controls:0.42%
—
—
—
—
—
—
cases:6.37%
controls:0.54%
cases:7.76%
controls:1.36%
12
28
251
2595
14
11
249
2612
—
—
—
16
14
235
2568
18
32
214
2313
ciclesonide; nasal
R01AD13 [43534836]
1.5e+00
2.6e+00
—
—
—
2.5e+00
1.8e+00
cases:4.56%
controls:1.07%
cases:5.32%
controls:0.42%
—
—
—
—
—
—
cases:6.37%
controls:0.54%
cases:7.76%
controls:1.36%
12
28
251
2595
14
11
249
2612
—
—
—
16
14
235
2568
18
32
214
2313
Sleep apnoea
G47.3 [45562094]
7.8e-01
1.1e+00
1.8e+00
1.0e+50
2.5e+00
1.4e+00
1.6e+00
cases:5.70%
controls:2.71%
cases:6.08%
controls:2.17%
cases:2.66%
controls:0.46%
cases:4.56%
controls:0.00%
cases:3.49%
controls:0.30%
cases:8.37%
controls:2.25%
cases:18.97%
controls:4.69%
15
71
248
2552
16
57
247
2566
7
12
256
2611
12
0
251
2623
9
8
249
2615
21
58
230
2524
44
110
188
2235
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.5e-01
1.0e+00
2.6e+00
—
1.8e+00
1.1e+00
1.0e+00
cases:17.11%
controls:8.92%
cases:13.69%
controls:5.34%
cases:12.55%
controls:1.03%
—
—
cases:4.26%
controls:0.76%
cases:14.34%
controls:5.31%
cases:27.59%
controls:12.32%
45
234
218
2389
36
140
227
2483
33
27
230
2596
—
11
20
247
2603
36
137
215
2445
64
289
168
2056
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.3e-01
9.9e-01
2.4e+00
—
1.9e+00
1.2e+00
1.0e+00
cases:16.35%
controls:8.62%
cases:12.93%
controls:5.22%
cases:9.89%
controls:0.99%
—
—
cases:4.26%
controls:0.69%
cases:14.34%
controls:5.03%
cases:27.16%
controls:11.90%
43
226
220
2397
34
137
229
2486
26
26
237
2597
—
11
18
247
2605
36
130
215
2452
63
279
169
2066
ciclosporin; oral, parenteral
L04AD01 [21603924]
1.6e+00
2.2e+00
—
—
—
2.7e+00
3.3e+00
cases:1.90%
controls:0.38%
cases:2.28%
controls:0.27%
—
—
—
—
—
—
cases:2.79%
controls:0.19%
cases:7.33%
controls:0.30%
5
10
258
2613
6
7
257
2616
—
—
—
7
5
244
2577
17
7
215
2338
Basophils [#/volume] in Blood
26444-0 [3006315]
7.0e-01
9.8e-01
2.4e+00
—
1.9e+00
1.1e+00
1.0e+00
cases:15.97%
controls:8.62%
cases:12.93%
controls:5.30%
cases:9.89%
controls:0.99%
—
—
cases:4.26%
controls:0.69%
cases:14.34%
controls:5.07%
cases:27.16%
controls:11.94%
42
226
221
2397
34
139
229
2484
26
26
237
2597
—
11
18
247
2605
36
131
215
2451
63
280
169
2065
INR in Blood by Coagulation assay
34714-6 [3032080]
6.6e-01
1.3e+00
2.3e+00
—
2.0e+00
1.5e+00
1.0e+00
cases:9.89%
controls:5.38%
cases:11.79%
controls:3.66%
cases:6.84%
controls:0.76%
—
—
cases:4.65%
controls:0.65%
cases:12.75%
controls:3.18%
cases:20.69%
controls:8.44%
26
141
237
2482
31
96
232
2527
18
20
245
2603
—
12
17
246
2606
32
82
219
2500
48
198
184
2147
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
6.7e-01
9.2e-01
2.4e+00
—
1.9e+00
1.1e+00
9.7e-01
cases:15.97%
controls:8.88%
cases:12.93%
controls:5.60%
cases:10.27%
controls:1.03%
—
—
cases:4.26%
controls:0.69%
cases:14.34%
controls:5.19%
cases:27.16%
controls:12.37%
42
233
221
2390
34
147
229
2476
27
27
236
2596
—
11
18
247
2605
36
134
215
2448
63
290
169
2055
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.3e+00
2.9e+00
—
—
1.0e+50
3.0e+00
2.1e+00
cases:3.80%
controls:1.07%
cases:8.37%
controls:0.50%
—
—
—
—
cases:3.10%
controls:0.00%
cases:6.37%
controls:0.35%
cases:10.34%
controls:1.45%
10
28
253
2595
22
13
241
2610
—
—
8
0
250
2623
16
9
235
2573
24
34
208
2311
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.1e-01
1.1e+00
2.7e+00
—
1.8e+00
1.2e+00
1.0e+00
cases:20.15%
controls:14.30%
cases:23.19%
controls:8.96%
cases:15.97%
controls:1.26%
—
—
cases:8.53%
controls:1.52%
cases:23.11%
controls:8.37%
cases:41.38%
controls:20.09%
53
375
210
2248
61
235
202
2388
42
33
221
2590
—
22
40
236
2583
58
216
193
2366
96
471
136
1874
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
7.4e-01
1.2e+00
1.8e+00
—
2.2e+00
1.1e+00
7.9e-01
cases:11.41%
controls:5.79%
cases:9.89%
controls:3.24%
cases:3.80%
controls:0.65%
—
—
cases:3.49%
controls:0.38%
cases:7.97%
controls:2.90%
cases:17.24%
controls:8.61%
30
152
233
2471
26
85
237
2538
10
17
253
2606
—
9
10
249
2613
20
75
231
2507
40
202
192
2143
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.3e-01
1.2e+00
1.8e+00
—
1.9e+00
1.0e+00
8.8e-01
cases:12.55%
controls:6.44%
cases:11.79%
controls:3.81%
cases:4.18%
controls:0.69%
—
—
cases:3.10%
controls:0.46%
cases:9.16%
controls:3.45%
cases:21.12%
controls:9.98%
33
169
230
2454
31
100
232
2523
11
18
252
2605
—
8
12
250
2611
23
89
228
2493
49
234
183
2111
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
1.3e+00
2.3e+00
—
—
—
2.9e+00
2.3e+00
cases:2.28%
controls:0.65%
cases:2.28%
controls:0.23%
—
—
—
—
—
—
cases:3.98%
controls:0.23%
cases:7.33%
controls:0.77%
6
17
257
2606
6
6
257
2617
—
—
—
10
6
241
2576
17
18
215
2327
Dyspnoea
R06.0 [45558449]
1.6e+00
2.2e+00
—
1.0e+50
—
2.2e+00
1.4e+00
cases:10.65%
controls:2.29%
cases:6.08%
controls:0.69%
—
—
cases:3.42%
controls:0.00%
—
—
cases:7.17%
controls:0.81%
cases:11.21%
controls:3.07%
28
60
235
2563
16
18
247
2605
—
9
0
254
2623
—
18
21
233
2561
26
72
206
2273
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
9.1e-01
1.3e+00
2.6e+00
—
—
1.3e+00
1.3e+00
cases:12.17%
controls:5.30%
cases:10.65%
controls:3.01%
cases:3.80%
controls:0.30%
—
—
—
—
cases:9.96%
controls:2.94%
cases:23.71%
controls:7.59%
32
139
231
2484
28
79
235
2544
10
8
253
2615
—
—
25
76
226
2506
55
178
177
2167
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.9e-01
1.1e+00
3.0e+00
—
1.8e+00
6.9e-01
8.7e-01
cases:20.15%
controls:13.42%
cases:18.25%
controls:7.24%
cases:14.07%
controls:0.80%
—
—
cases:4.65%
controls:0.80%
cases:13.94%
controls:7.51%
cases:36.21%
controls:19.19%
53
352
210
2271
48
190
215
2433
37
21
226
2602
—
12
21
246
2602
35
194
216
2388
84
450
148
1895
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
2.6e-01
1.0e+00
3.0e+00
—
—
1.9e+00
1.3e+00
cases:4.56%
controls:3.55%
cases:6.46%
controls:2.44%
cases:4.56%
controls:0.23%
—
—
—
—
cases:7.17%
controls:1.12%
cases:15.09%
controls:4.69%
12
93
251
2530
17
64
246
2559
12
6
251
2617
—
—
18
29
233
2553
35
110
197
2235
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.6e-01
1.2e+00
2.5e+00
—
1.9e+00
8.3e-01
7.8e-01
cases:16.35%
controls:12.05%
cases:18.63%
controls:6.60%
cases:7.60%
controls:0.65%
—
—
cases:4.26%
controls:0.65%
cases:13.94%
controls:6.58%
cases:33.62%
controls:18.81%
43
316
220
2307
49
173
214
2450
20
17
243
2606
—
11
17
247
2606
35
170
216
2412
78
441
154
1904
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.3e+00
2.9e+00
1.0e+50
—
—
2.2e+00
1.9e+00
cases:3.04%
controls:0.84%
cases:8.37%
controls:0.50%
cases:2.28%
controls:0.00%
—
—
—
—
cases:3.19%
controls:0.35%
cases:7.33%
controls:1.19%
8
22
255
2601
22
13
241
2610
6
0
257
2623
—
—
8
9
243
2573
17
28
215
2317
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.3e-01
5.9e-01
2.0e+00
3.2e+00
1.1e+00
3.9e-01
3.6e-01
cases:28.90%
controls:26.38%
cases:32.32%
controls:20.97%
cases:20.15%
controls:3.43%
cases:4.56%
controls:0.19%
cases:9.69%
controls:3.39%
cases:29.08%
controls:21.73%
cases:52.59%
controls:43.62%
76
692
187
1931
85
550
178
2073
53
90
210
2533
12
5
251
2618
25
89
233
2534
73
561
178
2021
122
1023
110
1322
Thorax X-ray examination
GD1AA [2001303617]
9.0e-01
1.9e+00
2.3e+00
1.0e+50
—
2.1e+00
2.0e+00
cases:14.83%
controls:6.60%
cases:9.89%
controls:1.64%
cases:1.90%
controls:0.19%
cases:7.22%
controls:0.00%
—
—
cases:10.76%
controls:1.51%
cases:31.90%
controls:5.84%
39
173
224
2450
26
43
237
2580
5
5
258
2618
19
0
244
2623
—
27
39
224
2543
74
137
158
2208
montelukast; oral
R03DC03 [21603356]
1.5e+00
1.9e+00
—
—
—
1.5e+00
1.9e+00
cases:11.03%
controls:2.71%
cases:9.51%
controls:1.52%
—
—
—
—
—
—
cases:7.17%
controls:1.67%
cases:16.38%
controls:2.99%
29
71
234
2552
25
40
238
2583
—
—
—
18
43
233
2539
38
70
194
2275
Emergency Room Visit
ER [9203]
6.7e-01
1.0e+00
1.5e+00
—
1.9e+00
9.4e-01
7.5e-01
cases:46.01%
controls:30.31%
cases:22.43%
controls:9.26%
cases:4.56%
controls:1.11%
—
—
cases:5.43%
controls:0.84%
cases:18.33%
controls:8.06%
cases:40.09%
controls:24.05%
121
795
142
1828
59
243
204
2380
12
29
251
2594
—
14
22
244
2601
46
208
205
2374
93
564
139
1781
Bronchiectasis
J47 [45605889]
2.9e+00
—
—
1.0e+50
—
—
3.8e+00
cases:4.18%
controls:0.23%
—
—
—
—
cases:6.08%
controls:0.00%
—
—
—
—
cases:8.62%
controls:0.21%
11
6
252
2617
—
—
16
0
247
2623
—
—
20
5
212
2340
doxycycline; oral, parenteral
J01AA02 [21602800]
8.7e-01
1.6e+00
—
—
1.7e+00
1.2e+00
1.3e+00
cases:34.98%
controls:18.38%
cases:20.15%
controls:4.84%
—
—
—
—
cases:3.10%
controls:0.61%
cases:14.74%
controls:4.92%
cases:39.66%
controls:14.67%
92
482
171
2141
53
127
210
2496
—
—
8
16
250
2607
37
127
214
2455
92
344
140
2001
Other specified special examinations
Z01.8 [45581003]
1.4e+00
2.4e+00
—
—
—
1.8e+00
1.0e+00
cases:7.60%
controls:2.06%
cases:5.70%
controls:0.53%
—
—
—
—
—
—
cases:3.98%
controls:0.66%
cases:9.05%
controls:3.37%
20
54
243
2569
15
14
248
2609
—
—
—
10
17
241
2565
21
79
211
2266
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.8e-01
8.7e-01
2.2e+00
—
1.5e+00
9.8e-01
9.3e-01
cases:15.21%
controls:10.03%
cases:13.69%
controls:6.21%
cases:11.41%
controls:1.41%
—
—
cases:4.65%
controls:1.03%
cases:14.74%
controls:6.08%
cases:28.02%
controls:13.30%
40
263
223
2360
36
163
227
2460
30
37
233
2586
—
12
27
246
2596
37
157
214
2425
65
312
167
2033
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.7e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.5e-01
cases:33.08%
controls:29.39%
cases:36.12%
controls:24.40%
cases:27.00%
controls:4.84%
cases:4.56%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.27%
87
771
176
1852
95
640
168
1983
71
127
192
2496
12
8
251
2615
28
97
230
2526
84
654
167
1928
132
1132
100
1213
MCH [Entitic mass]
28539-5 [3035941]
1.8e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.5e-01
cases:33.08%
controls:29.32%
cases:36.12%
controls:24.32%
cases:27.00%
controls:4.80%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.27%
87
769
176
1854
95
638
168
1985
71
126
192
2497
11
8
252
2615
28
97
230
2526
84
654
167
1928
132
1132
100
1213
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.8e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.4e-01
cases:33.08%
controls:29.32%
cases:36.12%
controls:24.40%
cases:27.00%
controls:4.80%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.36%
87
769
176
1854
95
640
168
1983
71
126
192
2497
11
8
252
2615
28
97
230
2526
84
654
167
1928
132
1134
100
1211
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.9e-01
5.8e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.4e-01
cases:33.46%
controls:29.32%
cases:36.50%
controls:24.44%
cases:27.00%
controls:4.88%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.36%
88
769
175
1854
96
641
167
1982
71
128
192
2495
11
8
252
2615
28
97
230
2526
84
654
167
1928
132
1134
100
1211
Cardiology
6 [38004451]
8.3e-01
1.0e+00
1.5e+00
—
1.8e+00
1.6e+00
1.1e+00
cases:12.55%
controls:5.91%
cases:7.22%
controls:2.71%
cases:2.28%
controls:0.53%
—
—
cases:3.10%
controls:0.53%
cases:11.55%
controls:2.59%
cases:20.26%
controls:7.59%
33
155
230
2468
19
71
244
2552
6
14
257
2609
—
8
14
250
2609
29
67
222
2515
47
178
185
2167
Platelets [#/volume] in Blood
26515-7 [3007461]
1.8e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
4.0e-01
3.5e-01
cases:33.08%
controls:29.24%
cases:36.12%
controls:24.32%
cases:27.00%
controls:4.84%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.29%
cases:56.90%
controls:48.23%
87
767
176
1856
95
638
168
1985
71
127
192
2496
11
8
252
2615
28
97
230
2526
84
653
167
1929
132
1131
100
1214
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.8e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.4e-01
cases:33.08%
controls:29.32%
cases:36.12%
controls:24.36%
cases:27.00%
controls:4.84%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.36%
87
769
176
1854
95
639
168
1984
71
127
192
2496
11
8
252
2615
28
97
230
2526
84
654
167
1928
132
1134
100
1211
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.8e-01
5.6e-01
2.0e+00
2.7e+00
1.2e+00
3.9e-01
3.5e-01
cases:33.08%
controls:29.32%
cases:36.12%
controls:24.40%
cases:27.00%
controls:4.88%
cases:4.18%
controls:0.30%
cases:10.85%
controls:3.70%
cases:33.47%
controls:25.33%
cases:56.90%
controls:48.27%
87
769
176
1854
95
640
168
1983
71
128
192
2495
11
8
252
2615
28
97
230
2526
84
654
167
1928
132
1132
100
1213
terbutaline; inhalant
R03AC03 [21603257]
1.6e+00
1.6e+00
—
—
—
1.5e+00
1.7e+00
cases:9.13%
controls:2.02%
cases:4.18%
controls:0.88%
—
—
—
—
—
—
cases:3.98%
controls:0.93%
cases:8.62%
controls:1.75%
24
53
239
2570
11
23
252
2600
—
—
—
10
24
241
2558
20
41
212
2304
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.2e+00
2.6e+00
—
—
—
1.9e+00
1.7e+00
cases:3.42%
controls:1.11%
cases:8.75%
controls:0.72%
—
—
—
—
—
—
cases:4.38%
controls:0.66%
cases:9.05%
controls:1.75%
9
29
254
2594
23
19
240
2604
—
—
—
11
17
240
2565
21
41
211
2304
Laboratory Visit
OMOP4822461 [32036]
1.2e-01
4.6e-01
1.7e+00
3.1e+00
9.5e-01
3.2e-01
1.8e-01
cases:36.88%
controls:34.04%
cases:42.21%
controls:31.53%
cases:34.98%
controls:9.23%
cases:10.27%
controls:0.50%
cases:18.60%
controls:8.16%
cases:40.64%
controls:33.23%
cases:58.19%
controls:53.73%
97
893
166
1730
111
827
152
1796
92
242
171
2381
27
13
236
2610
48
214
210
2409
102
858
149
1724
135
1260
97
1085
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.1e-01
8.7e-01
2.2e+00
—
1.6e+00
7.8e-01
6.6e-01
cases:28.14%
controls:22.23%
cases:27.76%
controls:13.92%
cases:17.87%
controls:2.25%
—
—
cases:8.91%
controls:1.87%
cases:27.49%
controls:14.76%
cases:50.00%
controls:34.12%
74
583
189
2040
73
365
190
2258
47
59
216
2564
—
23
49
235
2574
69
381
182
2201
116
800
116
1545
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.6e-01
7.3e-01
2.1e+00
—
2.5e+00
8.9e-01
6.1e-01
cases:9.51%
controls:7.47%
cases:8.37%
controls:4.23%
cases:3.42%
controls:0.42%
—
—
cases:3.49%
controls:0.30%
cases:8.76%
controls:3.80%
cases:20.26%
controls:12.15%
25
196
238
2427
22
111
241
2512
9
11
254
2612
—
9
8
249
2615
22
98
229
2484
47
285
185
2060
Standard cardiac ultrasound examination
FM1AE [2001303278]
1.3e+00
1.5e+00
—
—
—
1.7e+00
1.5e+00
cases:6.08%
controls:1.72%
cases:3.42%
controls:0.80%
—
—
—
—
—
—
cases:3.19%
controls:0.62%
cases:9.48%
controls:2.26%
16
45
247
2578
9
21
254
2602
—
—
—
8
16
243
2566
22
53
210
2292
Physical Medicine And Rehabilitation
25 [38004468]
2.5e-01
1.1e+00
—
—
2.3e+00
1.6e+00
8.9e-01
cases:7.98%
controls:6.33%
cases:6.08%
controls:2.21%
—
—
—
—
cases:2.33%
controls:0.23%
cases:7.57%
controls:1.59%
cases:14.66%
controls:6.61%
21
166
242
2457
16
58
247
2565
—
—
6
6
252
2617
19
41
232
2541
34
155
198
2190
fluticasone furoate
R03BA09 [45893496]
1.6e+00
1.4e+00
1.7e+00
—
1.5e+00
1.5e+00
1.2e+00
cases:12.55%
controls:2.86%
cases:7.22%
controls:1.83%
cases:2.66%
controls:0.50%
—
—
cases:2.33%
controls:0.53%
cases:6.77%
controls:1.63%
cases:9.91%
controls:3.11%
33
75
230
2548
19
48
244
2575
7
13
256
2610
—
6
14
252
2609
17
42
234
2540
23
73
209
2272
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.7e-01
6.4e-01
1.8e+00
2.0e+00
1.2e+00
4.8e-01
4.0e-01
cases:28.52%
controls:25.16%
cases:31.18%
controls:19.33%
cases:16.73%
controls:3.32%
cases:2.28%
controls:0.30%
cases:9.69%
controls:3.05%
cases:28.69%
controls:19.98%
cases:51.29%
controls:41.41%
75
660
188
1963
82
507
181
2116
44
87
219
2536
6
8
257
2615
25
80
233
2543
72
516
179
2066
119
971
113
1374
fluticasone; inhalant
R03BA05 [21603288]
1.6e+00
1.4e+00
1.6e+00
—
1.4e+00
1.4e+00
1.2e+00
cases:14.07%
controls:3.20%
cases:7.60%
controls:2.02%
cases:2.66%
controls:0.57%
—
—
cases:2.33%
controls:0.61%
cases:7.57%
controls:1.94%
cases:10.34%
controls:3.37%
37
84
226
2539
20
53
243
2570
7
15
256
2608
—
6
16
252
2607
19
50
232
2532
24
79
208
2266
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
4.2e-01
1.3e+00
1.8e+00
—
2.5e+00
4.3e-01
4.7e-01
cases:8.75%
controls:5.91%
cases:12.17%
controls:3.58%
cases:2.66%
controls:0.46%
—
—
cases:2.71%
controls:0.23%
cases:6.77%
controls:4.53%
cases:17.67%
controls:11.86%
23
155
240
2468
32
94
231
2529
7
12
256
2611
—
7
6
251
2617
17
117
234
2465
41
278
191
2067
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
2.4e-01
5.8e-01
2.0e+00
—
2.0e+00
8.2e-01
6.9e-01
cases:12.93%
controls:10.48%
cases:8.75%
controls:5.07%
cases:3.42%
controls:0.46%
—
—
cases:2.71%
controls:0.38%
cases:10.36%
controls:4.84%
cases:24.57%
controls:14.07%
34
275
229
2348
23
133
240
2490
9
12
254
2611
—
7
10
251
2613
26
125
225
2457
57
330
175
2015
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
2.0e+00
—
—
—
—
—
3.5e+00
cases:2.28%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:7.76%
controls:0.26%
6
8
257
2615
—
—
—
—
—
18
6
214
2339
ipratropium bromide; inhalant
R03BB01 [21603293]
2.7e+00
—
—
—
—
—
2.9e+00
cases:2.66%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:0.34%
7
5
256
2618
—
—
—
—
—
13
8
219
2337
Chronic obstructive pulmonary disease, unspecified
J44.9 [45548115]
2.6e+00
—
—
—
—
—
2.9e+00
cases:3.42%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.26%
9
7
254
2616
—
—
—
—
—
10
6
222
2339
Essential (primary) hypertension
I10 [45591453]
7.1e-01
8.3e-01
1.4e+00
—
1.9e+00
7.6e-01
5.8e-01
cases:17.49%
controls:9.45%
cases:10.27%
controls:4.77%
cases:3.80%
controls:0.99%
—
—
cases:4.65%
controls:0.72%
cases:10.36%
controls:5.15%
cases:22.84%
controls:14.20%
46
248
217
2375
27
125
236
2498
10
26
253
2597
—
12
19
246
2604
26
133
225
2449
53
333
179
2012
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.4e-01
6.2e-01
2.9e+00
—
—
1.6e+00
8.8e-01
cases:4.18%
controls:3.66%
cases:3.42%
controls:1.87%
cases:3.42%
controls:0.19%
—
—
—
—
cases:6.37%
controls:1.39%
cases:12.50%
controls:5.59%
11
96
252
2527
9
49
254
2574
9
5
254
2618
—
—
16
36
235
2546
29
131
203
2214
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
7.6e-01
1.9e+00
2.5e+00
—
—
1.5e+00
9.5e-01
cases:5.70%
controls:2.74%
cases:8.75%
controls:1.41%
cases:2.28%
controls:0.19%
—
—
—
—
cases:3.59%
controls:0.85%
cases:9.48%
controls:3.88%
15
72
248
2551
23
37
240
2586
6
5
257
2618
—
—
9
22
242
2560
22
91
210
2254
Normoblasts [#/volume] in Blood
715-3 [3021589]
5.1e-01
7.7e-01
1.9e+00
—
1.7e+00
9.2e-01
8.9e-01
cases:10.27%
controls:6.44%
cases:9.51%
controls:4.65%
cases:6.08%
controls:0.99%
—
—
cases:3.49%
controls:0.69%
cases:11.16%
controls:4.76%
cases:21.98%
controls:10.41%
27
169
236
2454
25
122
238
2501
16
26
247
2597
—
9
18
249
2605
28
123
223
2459
51
244
181
2101
High resolution CT examination of lungs
GD1DD [2001303632]
2.3e+00
—
—
1.0e+50
—
—
3.1e+00
cases:4.56%
controls:0.50%
—
—
—
—
cases:3.80%
controls:0.00%
—
—
—
—
cases:6.03%
controls:0.30%
12
13
251
2610
—
—
10
0
253
2623
—
—
14
7
218
2338
Mitochondria Ab [Titer] in Serum
20483-4 [3034770]
1.9e+00
3.4e+00
1.0e+50
—
—
—
1.9e+00
cases:2.28%
controls:0.34%
cases:7.22%
controls:0.27%
cases:2.28%
controls:0.00%
—
—
—
—
—
—
cases:3.02%
controls:0.47%
6
9
257
2614
19
7
244
2616
6
0
257
2623
—
—
—
7
11
225
2334
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
6.1e-01
1.3e+00
3.0e+00
—
—
1.0e+00
8.3e-01
cases:6.46%
controls:3.62%
cases:6.46%
controls:1.91%
cases:4.56%
controls:0.23%
—
—
—
—
cases:5.18%
controls:1.98%
cases:11.64%
controls:5.42%
17
95
246
2528
17
50
246
2573
12
6
251
2617
—
—
13
51
238
2531
27
127
205
2218
Dentistry
C5 [903277]
8.6e-01
1.7e+00
—
—
—
1.7e+00
1.6e+00
cases:3.80%
controls:1.64%
cases:4.18%
controls:0.80%
—
—
—
—
—
—
cases:4.38%
controls:0.85%
cases:9.05%
controls:1.88%
10
43
253
2580
11
21
252
2602
—
—
—
11
22
240
2560
21
44
211
2301
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.4e+00
1.0e+00
—
—
—
2.1e+00
1.6e+00
cases:5.32%
controls:1.41%
cases:2.66%
controls:0.95%
—
—
—
—
—
—
cases:5.18%
controls:0.70%
cases:9.48%
controls:2.09%
14
37
249
2586
7
25
256
2598
—
—
—
13
18
238
2564
22
49
210
2296
Spirometry
127783003 [4133840]
2.0e+00
—
—
1.0e+50
—
—
3.0e+00
cases:2.66%
controls:0.38%
—
—
—
—
cases:2.66%
controls:0.00%
—
—
—
—
cases:6.47%
controls:0.34%
7
10
256
2613
—
—
7
0
256
2623
—
—
15
8
217
2337
Thorax CT examination
GD1AD [2001303618]
—
—
—
—
—
2.5e+00
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.79%
controls:0.23%
cases:6.47%
controls:0.60%
—
—
—
—
—
7
6
244
2576
15
14
217
2331
prednisone
A07EA03 [21600655]
1.6e+00
—
—
—
—
1.9e+00
1.5e+00
cases:6.08%
controls:1.33%
—
—
—
—
—
—
—
—
cases:2.79%
controls:0.43%
cases:5.17%
controls:1.24%
16
35
247
2588
—
—
—
—
7
11
244
2571
12
29
220
2316
prednisone; oral
H02AB07 [21602735]
1.6e+00
—
—
—
—
1.9e+00
1.5e+00
cases:6.08%
controls:1.33%
—
—
—
—
—
—
—
—
cases:2.79%
controls:0.43%
cases:5.17%
controls:1.24%
16
35
247
2588
—
—
—
—
7
11
244
2571
12
29
220
2316
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
3.4e-01
7.3e-01
2.7e+00
—
—
1.4e+00
8.2e-01
cases:5.70%
controls:4.12%
cases:4.18%
controls:2.06%
cases:3.42%
controls:0.23%
—
—
—
—
cases:6.77%
controls:1.82%
cases:13.79%
controls:6.57%
15
108
248
2515
11
54
252
2569
9
6
254
2617
—
—
17
47
234
2535
32
154
200
2191
Inpatient Hospital
21 [8717]
3.4e-01
9.5e-01
1.3e+00
1.0e+50
2.0e+00
9.9e-01
1.0e+00
cases:35.36%
controls:27.95%
cases:19.39%
controls:8.50%
cases:3.80%
controls:1.11%
cases:10.27%
controls:0.00%
cases:5.43%
controls:0.80%
cases:17.93%
controls:7.47%
cases:38.79%
controls:18.68%
93
733
170
1890
51
223
212
2400
10
29
253
2594
27
0
236
2623
14
21
244
2602
45
193
206
2389
90
438
142
1907
alendronic acid; oral
M05BA04 [21604152]
—
1.9e+00
—
—
—
1.7e+00
1.3e+00
—
—
cases:2.66%
controls:0.42%
—
—
—
—
—
—
cases:3.19%
controls:0.62%
cases:4.74%
controls:1.28%
—
7
11
256
2612
—
—
—
8
16
243
2566
11
30
221
2315
Asthma
J45 [45596282]
1.5e+00
1.3e+00
—
—
—
1.9e+00
1.4e+00
cases:7.98%
controls:1.91%
cases:3.04%
controls:0.88%
—
—
—
—
—
—
cases:4.78%
controls:0.74%
cases:8.62%
controls:2.17%
21
50
242
2573
8
23
255
2600
—
—
—
12
19
239
2563
20
51
212
2294
salmeterol; inhalant
R03AC12 [21603266]
2.3e+00
—
—
—
—
—
2.5e+00
cases:3.42%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.21%
9
9
254
2614
—
—
—
—
—
6
5
226
2340
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
9.2e-01
1.9e+00
1.0e+50
—
—
1.6e+00
1.3e+00
cases:4.18%
controls:1.72%
cases:7.60%
controls:1.18%
cases:2.28%
controls:0.00%
—
—
—
—
cases:4.38%
controls:0.93%
cases:6.90%
controls:1.96%
11
45
252
2578
20
31
243
2592
6
0
257
2623
—
—
11
24
240
2558
16
46
216
2299
pH of Serum or Plasma
2753-2 [3018418]
5.2e-01
1.1e+00
2.2e+00
—
—
1.3e+00
7.6e-01
cases:5.70%
controls:3.47%
cases:5.70%
controls:1.91%
cases:2.66%
controls:0.30%
—
—
—
—
cases:5.58%
controls:1.59%
cases:11.21%
controls:5.59%
15
91
248
2532
15
50
248
2573
7
8
256
2615
—
—
14
41
237
2541
26
131
206
2214
Shortness of breath/dyspnoea
R02 [2002000883]
2.0e+00
2.6e+00
—
—
—
—
1.3e+00
cases:5.32%
controls:0.76%
cases:3.04%
controls:0.23%
—
—
—
—
—
—
—
—
cases:4.31%
controls:1.24%
14
20
249
2603
8
6
255
2617
—
—
—
—
10
29
222
2316
erdosteine; oral
R05CB15 [21603394]
1.4e+00
9.8e-01
—
—
—
1.5e+00
1.6e+00
cases:5.32%
controls:1.37%
cases:1.90%
controls:0.72%
—
—
—
—
—
—
cases:3.98%
controls:0.89%
cases:12.93%
controls:2.81%
14
36
249
2587
5
19
258
2604
—
—
—
10
23
241
2559
30
66
202
2279
Case Management Agency
251B00000X [38004193]
2.0e-01
1.5e-01
5.9e-01
3.3e+00
6.3e-01
3.3e-01
3.7e-01
cases:61.60%
controls:56.77%
cases:51.71%
controls:47.92%
cases:28.14%
controls:17.84%
cases:23.19%
controls:1.07%
cases:27.52%
controls:16.89%
cases:58.57%
controls:50.43%
cases:77.59%
controls:70.45%
162
1489
101
1134
136
1257
127
1366
74
468
189
2155
61
28
202
2595
71
443
187
2180
147
1302
104
1280
180
1652
52
693
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
3.5e-01
6.5e-01
2.5e+00
—
—
1.2e+00
7.9e-01
cases:6.46%
controls:4.65%
cases:4.56%
controls:2.44%
cases:3.04%
controls:0.27%
—
—
—
—
cases:6.77%
controls:2.09%
cases:14.66%
controls:7.21%
17
122
246
2501
12
64
251
2559
8
7
255
2616
—
—
17
54
234
2528
34
169
198
2176
pravastatin; oral
C10AA03 [21601858]
—
2.0e+00
—
—
—
1.8e+00
2.4e+00
—
—
cases:2.28%
controls:0.30%
—
—
—
—
—
—
cases:1.99%
controls:0.35%
cases:6.03%
controls:0.55%
—
6
8
257
2615
—
—
—
5
9
246
2573
14
13
218
2332
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
6.9e-02
2.6e-01
1.7e+00
2.8e+00
6.0e-01
1.4e-01
1.1e-01
cases:23.95%
controls:22.72%
cases:21.67%
controls:17.65%
cases:15.59%
controls:3.35%
cases:3.04%
controls:0.19%
cases:5.04%
controls:2.82%
cases:19.92%
controls:17.82%
cases:39.66%
controls:37.14%
63
596
200
2027
57
463
206
2160
41
88
222
2535
8
5
255
2618
13
74
245
2549
50
460
201
2122
92
871
140
1474
furosemide; oral, parenteral
C03CA01 [21601518]
1.0e+00
1.0e+00
—
—
1.4e+00
1.1e+00
1.3e+00
cases:6.84%
controls:2.55%
cases:5.32%
controls:1.94%
—
—
—
—
cases:1.94%
controls:0.50%
cases:6.37%
controls:2.25%
cases:11.64%
controls:3.62%
18
67
245
2556
14
51
249
2572
—
—
5
13
253
2610
16
58
235
2524
27
85
205
2260
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.1e+00
1.3e+00
—
—
—
1.8e+00
1.4e+00
cases:4.94%
controls:1.72%
cases:2.28%
controls:0.65%
—
—
—
—
—
—
cases:5.58%
controls:0.93%
cases:9.48%
controls:2.56%
13
45
250
2578
6
17
257
2606
—
—
—
14
24
237
2558
22
60
210
2285
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.0e+00
1.2e+00
—
—
—
1.9e+00
1.4e+00
cases:8.37%
controls:3.16%
cases:3.04%
controls:0.91%
—
—
—
—
—
—
cases:6.37%
controls:1.01%
cases:12.07%
controls:3.37%
22
83
241
2540
8
24
255
2599
—
—
—
16
26
235
2556
28
79
204
2266
Cough
R05 [45606792]
6.3e-01
2.6e+00
—
—
—
1.7e+00
5.6e-01
cases:3.80%
controls:2.06%
cases:4.56%
controls:0.34%
—
—
—
—
—
—
cases:3.59%
controls:0.70%
cases:4.74%
controls:2.77%
10
54
253
2569
12
9
251
2614
—
—
—
9
18
242
2564
11
65
221
2280
Flexible bronchoscopy
UGC12 [2001303610]
1.8e+00
—
—
—
—
—
2.5e+00
cases:3.42%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:0.47%
9
16
254
2607
—
—
—
—
—
13
11
219
2334
mometasone; nasal
R01AD09 [21605051]
8.2e-01
1.1e+00
—
—
1.7e+00
1.2e+00
1.0e+00
cases:16.35%
controls:7.89%
cases:7.60%
controls:2.74%
—
—
—
—
cases:2.71%
controls:0.50%
cases:9.96%
controls:3.10%
cases:20.69%
controls:8.53%
43
207
220
2416
20
72
243
2551
—
—
7
13
251
2610
25
80
226
2502
48
200
184
2145
Upper gastrointestinal surgery
106 [44777669]
6.1e-01
5.8e-01
—
—
2.3e+00
1.1e+00
6.8e-01
cases:12.93%
controls:7.43%
cases:5.70%
controls:3.28%
—
—
—
—
cases:1.94%
controls:0.19%
cases:7.57%
controls:2.59%
cases:15.09%
controls:8.23%
34
195
229
2428
15
86
248
2537
—
—
5
5
253
2618
19
67
232
2515
35
193
197
2152
Leukocytes [#/volume] in Urine
30405-5 [3018095]
4.1e-01
6.6e-01
2.1e+00
—
—
1.2e+00
7.6e-01
cases:6.46%
controls:4.38%
cases:4.56%
controls:2.40%
cases:3.42%
controls:0.42%
—
—
—
—
cases:7.17%
controls:2.17%
cases:15.52%
controls:7.89%
17
115
246
2508
12
63
251
2560
9
11
254
2612
—
—
18
56
233
2526
36
185
196
2160
vilanterol and fluticasone furoate
R03AK10 [43534841]
1.2e+00
—
—
—
—
2.1e+00
2.1e+00
cases:1.90%
controls:0.57%
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.46%
cases:6.03%
controls:0.81%
5
15
258
2608
—
—
—
—
9
12
242
2570
14
19
218
2326
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
4.5e-01
2.8e+00
—
—
—
1.5e+00
1.2e+00
cases:1.90%
controls:1.22%
cases:7.22%
controls:0.46%
—
—
—
—
—
—
cases:2.79%
controls:0.66%
cases:8.19%
controls:2.60%
5
32
258
2591
19
12
244
2611
—
—
—
7
17
244
2565
19
61
213
2284
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.0e+00
—
—
—
—
2.1e+00
2.0e+00
cases:2.28%
controls:0.84%
—
—
—
—
—
—
—
—
cases:3.59%
controls:0.46%
cases:7.33%
controls:1.11%
6
22
257
2601
—
—
—
—
9
12
242
2570
17
26
215
2319
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
6.9e-01
1.4e+00
2.5e+00
—
—
—
-3.4e-01
cases:5.70%
controls:2.94%
cases:5.70%
controls:1.45%
cases:2.28%
controls:0.19%
—
—
—
—
—
—
cases:3.02%
controls:4.18%
15
77
248
2546
15
38
248
2585
6
5
257
2618
—
—
—
7
98
225
2247
Outpatient Hospital
22 [8756]
3.7e-01
6.9e-01
1.2e+00
—
1.9e+00
1.1e+00
9.0e-01
cases:29.28%
controls:22.15%
cases:11.79%
controls:6.25%
cases:2.28%
controls:0.69%
—
—
cases:3.10%
controls:0.50%
cases:13.55%
controls:4.76%
cases:29.31%
controls:14.37%
77
581
186
2042
31
164
232
2459
6
18
257
2605
—
8
13
250
2610
34
123
217
2459
68
337
164
2008
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
8.1e-01
1.0e+00
—
—
—
1.2e+00
8.8e-01
cases:15.97%
controls:7.78%
cases:6.84%
controls:2.63%
—
—
—
—
—
—
cases:5.98%
controls:1.86%
cases:17.24%
controls:7.97%
42
204
221
2419
18
69
245
2554
—
—
—
15
48
236
2534
40
187
192
2158
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
2.8e-01
2.7e+00
—
—
—
1.4e+00
1.2e+00
cases:1.90%
controls:1.45%
cases:7.60%
controls:0.57%
—
—
—
—
—
—
cases:2.79%
controls:0.74%
cases:8.62%
controls:2.77%
5
38
258
2585
20
15
243
2608
—
—
—
7
19
244
2563
20
65
212
2280
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.9e-01
9.0e-01
1.2e+00
—
9.5e-01
1.2e+00
8.8e-01
cases:26.24%
controls:12.73%
cases:14.07%
controls:6.25%
cases:4.18%
controls:1.33%
—
—
cases:3.10%
controls:1.22%
cases:19.12%
controls:6.86%
cases:32.33%
controls:16.50%
69
334
194
2289
37
164
226
2459
11
35
252
2588
—
8
32
250
2591
48
177
203
2405
75
387
157
1958
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.4e-01
5.5e-01
1.9e+00
—
1.3e+00
4.1e-01
3.3e-01
cases:26.62%
controls:23.94%
cases:26.62%
controls:17.31%
cases:14.83%
controls:2.52%
—
—
cases:8.14%
controls:2.36%
cases:24.70%
controls:17.85%
cases:45.69%
controls:37.70%
70
628
193
1995
70
454
193
2169
39
66
224
2557
—
21
62
237
2561
62
461
189
2121
106
884
126
1461
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
9.6e-01
1.0e+00
—
—
2.3e+00
8.2e-01
1.4e+00
cases:4.94%
controls:1.94%
cases:3.04%
controls:1.14%
—
—
—
—
cases:2.33%
controls:0.23%
cases:3.19%
controls:1.43%
cases:15.52%
controls:4.26%
13
51
250
2572
8
30
255
2593
—
—
6
6
252
2617
8
37
243
2545
36
100
196
2245
Spirometry study
18759-1 [3000492]
7.3e-01
2.0e+00
—
—
—
1.5e+00
1.7e+00
cases:3.80%
controls:1.87%
cases:3.04%
controls:0.42%
—
—
—
—
—
—
cases:3.19%
controls:0.74%
cases:11.64%
controls:2.30%
10
49
253
2574
8
11
255
2612
—
—
—
8
19
243
2563
27
54
205
2291
Abdominal ultrasound examination
JN3AE [2001305555]
3.0e-01
—
—
—
—
2.1e+00
1.7e+00
cases:1.90%
controls:1.41%
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.31%
cases:3.88%
controls:0.77%
5
37
258
2586
—
—
—
—
6
8
245
2574
9
18
223
2327
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.3e+00
2.0e+00
—
—
—
1.4e+00
1.7e+00
cases:2.28%
controls:0.61%
cases:3.04%
controls:0.42%
—
—
—
—
—
—
cases:2.39%
controls:0.58%
cases:6.03%
controls:1.15%
6
16
257
2607
8
11
255
2612
—
—
—
6
15
245
2567
14
27
218
2318
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.3e-01
5.5e-01
1.9e+00
—
1.3e+00
3.8e-01
3.2e-01
cases:26.62%
controls:24.09%
cases:27.00%
controls:17.58%
cases:15.21%
controls:2.67%
—
—
cases:8.14%
controls:2.40%
cases:24.70%
controls:18.28%
cases:46.12%
controls:38.25%
70
632
193
1991
71
461
192
2162
40
70
223
2553
—
21
63
237
2560
62
472
189
2110
107
897
125
1448
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
-1.0e+50
1.2e+00
—
—
—
2.2e+00
1.4e+00
cases:0.00%
controls:1.03%
cases:1.90%
controls:0.57%
—
—
—
—
—
—
cases:3.19%
controls:0.35%
cases:7.76%
controls:2.00%
0
27
263
2596
5
15
258
2608
—
—
—
8
9
243
2573
18
47
214
2298
ambroxol; oral
R05CB06 [21603385]
1.0e+00
1.5e+00
—
—
—
1.2e+00
1.1e+00
cases:6.84%
controls:2.52%
cases:3.42%
controls:0.76%
—
—
—
—
—
—
cases:1.99%
controls:0.62%
cases:9.05%
controls:3.33%
18
66
245
2557
9
20
254
2603
—
—
—
5
16
246
2566
21
78
211
2267
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
1.0e+00
1.8e+00
—
—
—
—
1.8e+00
cases:2.66%
controls:0.95%
cases:2.66%
controls:0.46%
—
—
—
—
—
—
—
—
cases:5.17%
controls:0.85%
7
25
256
2598
7
12
256
2611
—
—
—
—
12
20
220
2325
CBC panel - Blood by Automated count
58410-2 [40761511]
1.9e-01
5.1e-01
1.8e+00
—
1.3e+00
4.7e-01
3.4e-01
cases:28.52%
controls:24.90%
cases:26.24%
controls:17.54%
cases:14.45%
controls:2.78%
—
—
cases:6.59%
controls:1.83%
cases:24.70%
controls:17.04%
cases:46.98%
controls:38.59%
75
653
188
1970
69
460
194
2163
38
73
225
2550
—
17
48
241
2575
62
440
189
2142
109
905
123
1440
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
—
—
—
—
—
—
3.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.62%
controls:0.26%
—
—
—
—
—
—
20
6
212
2339
Bacteria identified in Isolate by Culture
43409-2 [3042936]
-4.3e-02
—
—
—
—
2.0e+00
1.6e+00
cases:1.90%
controls:1.98%
—
—
—
—
—
—
—
—
cases:3.19%
controls:0.46%
cases:9.05%
controls:1.92%
5
52
258
2571
—
—
—
—
8
12
243
2570
21
45
211
2300
Medical doctor
Z2221 [2001311556]
3.2e-01
1.2e+00
—
1.0e+50
—
1.8e+00
1.7e+00
cases:5.70%
controls:4.19%
cases:2.66%
controls:0.80%
—
—
cases:2.28%
controls:0.00%
—
—
cases:3.59%
controls:0.62%
cases:9.91%
controls:2.00%
15
110
248
2513
7
21
256
2602
—
6
0
257
2623
—
9
16
242
2566
23
47
209
2298
Physiotherapist
Z3226 [2001311560]
-6.9e-02
1.5e+00
—
—
—
2.0e+00
1.5e+00
cases:2.28%
controls:2.44%
cases:1.90%
controls:0.42%
—
—
—
—
—
—
cases:2.79%
controls:0.39%
cases:5.60%
controls:1.36%
6
64
257
2559
5
11
258
2612
—
—
—
7
10
244
2572
13
32
219
2313
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
1.6e+00
3.4e+00
1.0e+50
—
—
—
1.7e+00
cases:1.90%
controls:0.38%
cases:7.60%
controls:0.27%
cases:2.28%
controls:0.00%
—
—
—
—
—
—
cases:2.59%
controls:0.47%
5
10
258
2613
20
7
243
2616
6
0
257
2623
—
—
—
6
11
226
2334
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
6.6e-01
2.3e+00
—
—
—
1.1e+00
1.1e+00
cases:3.04%
controls:1.60%
cases:7.22%
controls:0.76%
—
—
—
—
—
—
cases:3.19%
controls:1.08%
cases:8.62%
controls:3.16%
8
42
255
2581
19
20
244
2603
—
—
—
8
28
243
2554
20
74
212
2271
Acute bronchitis
J20 [45581849]
1.9e+00
—
—
—
—
—
1.5e+00
cases:2.66%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:5.17%
controls:1.24%
7
11
256
2612
—
—
—
—
—
12
29
220
2316
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.5e+00
—
—
—
—
1.5e+00
1.8e+00
cases:7.60%
controls:1.83%
—
—
—
—
—
—
—
—
cases:1.99%
controls:0.46%
cases:8.19%
controls:1.45%
20
48
243
2575
—
—
—
—
5
12
246
2570
19
34
213
2311
Physiotherapy
R4110 [2001310233]
2.2e-01
1.1e+00
—
—
—
1.9e+00
1.4e+00
cases:4.94%
controls:4.00%
cases:3.80%
controls:1.30%
—
—
—
—
—
—
cases:6.37%
controls:1.05%
cases:12.50%
controls:3.45%
13
105
250
2518
10
34
253
2589
—
—
—
16
27
235
2555
29
81
203
2264
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
4.7e-01
1.7e+00
—
—
—
1.2e+00
1.5e+00
cases:2.66%
controls:1.68%
cases:4.56%
controls:0.84%
—
—
—
—
—
—
cases:2.79%
controls:0.85%
cases:7.76%
controls:1.83%
7
44
256
2579
12
22
251
2601
—
—
—
7
22
244
2560
18
43
214
2302
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.2e+00
1.8e+00
—
—
—
1.3e+00
1.4e+00
cases:2.28%
controls:0.69%
cases:3.04%
controls:0.50%
—
—
—
—
—
—
cases:2.39%
controls:0.66%
cases:5.60%
controls:1.49%
6
18
257
2605
8
13
255
2610
—
—
—
6
17
245
2565
13
35
219
2310
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.3e+00
1.8e+00
—
—
—
1.4e+00
1.3e+00
cases:1.90%
controls:0.53%
cases:3.04%
controls:0.50%
—
—
—
—
—
—
cases:2.39%
controls:0.62%
cases:5.60%
controls:1.54%
5
14
258
2609
8
13
255
2610
—
—
—
6
16
245
2566
13
36
219
2309
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
8.5e-01
1.1e+00
—
—
2.3e+00
1.1e+00
8.3e-01
cases:6.08%
controls:2.71%
cases:4.18%
controls:1.45%
—
—
—
—
cases:1.94%
controls:0.19%
cases:4.78%
controls:1.67%
cases:9.91%
controls:4.56%
16
71
247
2552
11
38
252
2585
—
—
5
5
253
2618
12
43
239
2539
23
107
209
2238
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.3e+00
1.8e+00
—
—
—
1.3e+00
1.3e+00
cases:2.28%
controls:0.65%
cases:3.04%
controls:0.50%
—
—
—
—
—
—
cases:2.39%
controls:0.66%
cases:5.17%
controls:1.45%
6
17
257
2606
8
13
255
2610
—
—
—
6
17
245
2565
12
34
220
2311
pH of Specimen
17433-4 [3019225]
1.1e+00
1.7e+00
—
—
—
1.5e+00
1.4e+00
cases:3.80%
controls:1.33%
cases:3.42%
controls:0.65%
—
—
—
—
—
—
cases:3.19%
controls:0.74%
cases:5.60%
controls:1.41%
10
35
253
2588
9
17
254
2606
—
—
—
8
19
243
2563
13
33
219
2312
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
7.1e-01
1.6e+00
—
—
—
1.8e+00
1.3e+00
cases:3.80%
controls:1.91%
cases:2.28%
controls:0.46%
—
—
—
—
—
—
cases:2.79%
controls:0.46%
cases:6.03%
controls:1.75%
10
50
253
2573
6
12
257
2611
—
—
—
7
12
244
2570
14
41
218
2304
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.5e+00
1.0e+00
—
—
—
—
1.6e+00
cases:7.60%
controls:1.79%
cases:1.90%
controls:0.69%
—
—
—
—
—
—
—
—
cases:8.19%
controls:1.83%
20
47
243
2576
5
18
258
2605
—
—
—
—
19
43
213
2302
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
8.3e-01
—
—
—
—
3.1e+00
1.5e+00
cases:1.90%
controls:0.84%
—
—
—
—
—
—
—
—
cases:4.78%
controls:0.23%
cases:3.02%
controls:0.68%
5
22
258
2601
—
—
—
—
12
6
239
2576
7
16
225
2329
Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma
1825-9 [3026285]
—
—
1.0e+50
—
1.0e+50
1.0e+50
3.0e+00
—
—
—
—
cases:7.60%
controls:0.00%
—
—
cases:2.33%
controls:0.00%
cases:2.39%
controls:0.00%
cases:4.31%
controls:0.21%
—
—
20
0
243
2623
—
6
0
252
2623
6
0
245
2582
10
5
222
2340
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
9.1e-01
8.5e-01
—
—
—
1.8e+00
1.2e+00
cases:3.80%
controls:1.56%
cases:2.28%
controls:0.99%
—
—
—
—
—
—
cases:3.59%
controls:0.62%
cases:8.19%
controls:2.56%
10
41
253
2582
6
26
257
2597
—
—
—
9
16
242
2566
19
60
213
2285
Diffusion capacity of lung
54715006 [4182985]
-1.0e+50
—
—
1.0e+50
—
—
3.0e+00
cases:0.00%
controls:0.19%
—
—
—
—
cases:3.04%
controls:0.00%
—
—
—
—
cases:6.47%
controls:0.34%
0
5
263
2618
—
—
8
0
255
2623
—
—
15
8
217
2337
azithromycin; oral, parenteral
J01FA10 [21602978]
6.4e-01
6.8e-01
—
—
—
1.3e+00
1.0e+00
cases:17.11%
controls:9.84%
cases:4.56%
controls:2.36%
—
—
—
—
—
—
cases:7.17%
controls:2.09%
cases:17.24%
controls:6.82%
45
258
218
2365
12
62
251
2561
—
—
—
18
54
233
2528
40
160
192
2185
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.6e+00
1.4e+00
—
—
1.0e+50
1.1e+00
1.4e+00
cases:4.18%
controls:0.88%
cases:1.90%
controls:0.46%
—
—
—
—
cases:1.94%
controls:0.00%
cases:2.39%
controls:0.77%
cases:6.47%
controls:1.75%
11
23
252
2600
5
12
258
2611
—
—
5
0
253
2623
6
20
245
2562
15
41
217
2304
calcium (different salts in combination); oral
A12AA20 [21600872]
3.2e-01
8.5e-01
6.7e-01
—
—
7.8e-01
1.3e+00
cases:8.37%
controls:6.21%
cases:10.65%
controls:4.84%
cases:2.28%
controls:1.18%
—
—
—
—
cases:10.76%
controls:5.23%
cases:22.84%
controls:7.33%
22
163
241
2460
28
127
235
2496
6
31
257
2592
—
—
27
135
224
2447
53
172
179
2173
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.03%
controls:0.34%
—
—
—
—
—
—
14
8
218
2337
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
9.2e-01
1.7e+00
—
—
—
—
1.2e+00
cases:4.56%
controls:1.87%
cases:3.80%
controls:0.72%
—
—
—
—
—
—
—
—
cases:6.47%
controls:2.00%
12
49
251
2574
10
19
253
2604
—
—
—
—
15
47
217
2298
Social worker
Z2446 [2001311559]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.17%
controls:0.30%
—
—
—
—
—
—
12
7
220
2338
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:0.34%
—
—
—
—
—
—
13
8
219
2337
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
8.3e-01
1.6e+00
—
—
—
1.2e+00
1.2e+00
cases:3.42%
controls:1.52%
cases:3.42%
controls:0.72%
—
—
—
—
—
—
cases:2.79%
controls:0.85%
cases:7.33%
controls:2.22%
9
40
254
2583
9
19
254
2604
—
—
—
7
22
244
2560
17
52
215
2293
Pneumonia, unspecified
J18.9 [45601123]
1.1e+00
1.1e+00
—
1.0e+50
—
1.3e+00
1.7e+00
cases:6.08%
controls:2.06%
cases:2.28%
controls:0.76%
—
—
cases:1.90%
controls:0.00%
—
—
cases:2.79%
controls:0.77%
cases:13.79%
controls:2.86%
16
54
247
2569
6
20
257
2603
—
5
0
258
2623
—
7
20
244
2562
32
67
200
2278
nystatin
D01AA01 [21601911]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.21%
—
—
—
—
—
—
8
5
224
2340
nystatin; vaginal
G01AA01 [21602363]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.21%
—
—
—
—
—
—
8
5
224
2340
metronidazole and furazolidone
P01AB51 [45893518]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.21%
—
—
—
—
—
—
8
5
224
2340
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
-1.0e+50
—
—
—
—
—
2.8e+00
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.21%
0
11
263
2612
—
—
—
—
—
8
5
224
2340
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.30%
—
—
—
—
—
—
11
7
221
2338
olodaterol and tiotropium bromide
R03AL06 [1588644]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.21%
—
—
—
—
—
—
7
5
225
2340
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
2.4e-01
5.5e-01
—
—
—
1.5e+00
1.2e+00
cases:4.18%
controls:3.32%
cases:1.90%
controls:1.11%
—
—
—
—
—
—
cases:3.98%
controls:0.93%
cases:9.05%
controls:2.99%
11
87
252
2536
5
29
258
2594
—
—
—
10
24
241
2558
21
70
211
2275
ebastine; oral
R06AX22 [21603521]
1.1e+00
1.6e+00
—
—
—
9.3e-01
1.1e+00
cases:4.94%
controls:1.75%
cases:4.18%
controls:0.91%
—
—
—
—
—
—
cases:2.79%
controls:1.12%
cases:6.03%
controls:2.09%
13
46
250
2577
11
24
252
2599
—
—
—
7
29
244
2553
14
49
218
2296
triamcinolone and antiinfectives
S02CA04 [21605176]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.26%
—
—
—
—
—
—
8
6
224
2339
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.1e-01
9.2e-01
8.1e-01
—
1.2e+00
9.1e-01
7.7e-01
cases:13.31%
controls:7.70%
cases:8.37%
controls:3.51%
cases:2.28%
controls:1.03%
—
—
cases:3.10%
controls:0.95%
cases:9.16%
controls:3.91%
cases:17.24%
controls:8.78%
35
202
228
2421
22
92
241
2531
6
27
257
2596
—
8
25
250
2598
23
101
228
2481
40
206
192
2139
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
-1.0e+50
—
—
—
—
—
2.6e+00
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.34%
0
14
263
2609
—
—
—
—
—
10
8
222
2337
Genetic counselling
Z31.5 [45590715]
—
-1.0e+50
—
—
—
2.5e+00
1.6e+00
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:2.39%
controls:0.19%
cases:2.59%
controls:0.55%
—
0
11
263
2612
—
—
—
6
5
245
2577
6
13
226
2332
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.21%
—
—
—
—
—
—
6
5
226
2340
Thoracal epidural anesthesia
WX302 [2001310795]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.21%
—
—
—
—
—
—
6
5
226
2340
Bacteria [Presence] in Urine
87829-8 [36304419]
1.5e-01
6.9e-01
—
—
—
1.6e+00
8.7e-01
cases:4.18%
controls:3.62%
cases:3.42%
controls:1.75%
—
—
—
—
—
—
cases:6.37%
controls:1.32%
cases:12.07%
controls:5.42%
11
95
252
2528
9
46
254
2577
—
—
—
16
34
235
2548
28
127
204
2218
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.26%
—
—
—
—
—
—
7
6
225
2339
More than five and less than seven hours
ZXE30 [2001311411]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.26%
—
—
—
—
—
—
7
6
225
2339
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.26%
—
—
—
—
—
—
7
6
225
2339
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
6.6e-01
8.1e-01
—
—
—
1.4e+00
1.0e+00
cases:6.08%
controls:3.24%
cases:3.04%
controls:1.37%
—
—
—
—
—
—
cases:6.37%
controls:1.59%
cases:12.50%
controls:4.78%
16
85
247
2538
8
36
255
2587
—
—
—
16
41
235
2541
29
112
203
2233
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.30%
—
—
—
—
—
—
8
7
224
2338
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.1e-01
4.9e-01
1.9e+00
—
9.9e-01
4.2e-01
5.8e-01
cases:20.15%
controls:16.93%
cases:21.67%
controls:14.49%
cases:13.31%
controls:2.25%
—
—
cases:5.43%
controls:2.10%
cases:21.12%
controls:14.99%
cases:43.53%
controls:30.19%
53
444
210
2179
57
380
206
2243
35
59
228
2564
—
14
55
244
2568
53
387
198
2195
101
708
131
1637
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.34%
—
—
—
—
—
—
9
8
223
2337
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
1.4e+00
—
—
—
—
—
2.4e+00
cases:2.66%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
cases:7.33%
controls:0.68%
7
18
256
2605
—
—
—
—
—
17
16
215
2329
roxithromycin; oral
J01FA06 [21602974]
1.1e+00
1.3e+00
—
—
—
1.4e+00
1.3e+00
cases:11.79%
controls:4.38%
cases:3.42%
controls:0.95%
—
—
—
—
—
—
cases:2.79%
controls:0.70%
cases:8.62%
controls:2.52%
31
115
232
2508
9
25
254
2598
—
—
—
7
18
244
2564
20
59
212
2286
Pain in thoracic spine
M54.6 [45606247]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.99%
controls:0.19%
—
—
—
—
—
—
—
5
5
246
2577
—
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.6e-01
4.8e-01
—
—
2.3e+00
6.2e-01
5.5e-01
cases:7.98%
controls:5.72%
cases:5.32%
controls:3.35%
—
—
—
—
cases:1.94%
controls:0.19%
cases:4.78%
controls:2.63%
cases:13.36%
controls:8.14%
21
150
242
2473
14
88
249
2535
—
—
5
5
253
2618
12
68
239
2514
31
191
201
2154
Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
46083-2 [3043362]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.26%
—
—
—
—
—
—
6
6
226
2339
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.26%
—
—
—
—
—
—
6
6
226
2339
Intensive care
WX872 [2001310844]
-1.0e+50
—
—
—
—
—
2.3e+00
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.26%
0
5
263
2618
—
—
—
—
—
6
6
226
2339
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
FXA00 [2001303347]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.26%
—
—
—
—
—
—
6
6
226
2339
Overnight pulse oximetry
252568001 [4091874]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.21%
—
—
—
—
—
—
5
5
227
2340
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.21%
—
—
—
—
—
—
5
5
227
2340
Spirometry at the office
SPAT1059 [2001700160]
2.3e+00
—
—
—
—
—
—
cases:2.66%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
256
2616
—
—
—
—
—
—
Fever, unspecified
R50.9 [45582716]
1.2e+00
2.3e+00
—
—
—
—
1.4e+00
cases:3.42%
controls:1.07%
cases:2.28%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.02%
9
28
254
2595
6
6
257
2617
—
—
—
—
9
24
223
2321
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
—
2.3e+00
—
—
—
—
1.5e+00
—
—
cases:2.28%
controls:0.23%
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.47%
—
6
6
257
2617
—
—
—
—
5
11
227
2334
Acute bronchitis, unspecified
J20.9 [45562445]
1.0e+00
1.9e+00
—
—
—
1.7e+00
1.3e+00
cases:6.08%
controls:2.25%
cases:2.28%
controls:0.34%
—
—
—
—
—
—
cases:2.39%
controls:0.46%
cases:7.33%
controls:2.17%
16
59
247
2564
6
9
257
2614
—
—
—
6
12
245
2570
17
51
215
2294
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.4e-01
7.0e-01
—
—
—
8.4e-01
7.7e-01
cases:30.42%
controls:21.92%
cases:12.17%
controls:6.44%
—
—
—
—
—
—
cases:11.55%
controls:5.34%
cases:34.05%
controls:19.36%
80
575
183
2048
32
169
231
2454
—
—
—
29
138
222
2444
79
454
153
1891
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
1.5e-01
1.1e+00
—
—
—
1.5e+00
8.2e-01
cases:3.42%
controls:2.97%
cases:2.28%
controls:0.76%
—
—
—
—
—
—
cases:4.38%
controls:1.05%
cases:9.91%
controls:4.61%
9
78
254
2545
6
20
257
2603
—
—
—
11
27
240
2555
23
108
209
2237
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.51%
—
—
—
—
—
—
11
12
221
2333
Dental impressions
SBB10 [2001310299]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.47%
—
—
—
—
—
—
10
11
222
2334
omeprazole; oral, parenteral
A02BC01 [21600096]
8.4e-01
2.0e-01
—
—
—
1.3e+00
9.8e-01
cases:7.60%
controls:3.43%
cases:1.90%
controls:1.56%
—
—
—
—
—
—
cases:4.78%
controls:1.39%
cases:7.76%
controls:3.07%
20
90
243
2533
5
41
258
2582
—
—
—
12
36
239
2546
18
72
214
2273
Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma
19176-7 [3015916]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.43%
—
—
—
—
—
—
9
10
223
2335
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.38%
—
—
—
—
—
—
8
9
224
2336
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
2.2e+00
—
—
—
1.5e+00
6.9e-01
—
—
cases:3.42%
controls:0.38%
—
—
—
—
—
—
cases:1.99%
controls:0.46%
cases:3.02%
controls:1.54%
—
9
10
254
2613
—
—
—
5
12
246
2570
7
36
225
2309
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
6.2e-01
2.2e+00
—
—
—
1.5e+00
5.4e-01
cases:4.18%
controls:2.29%
cases:7.98%
controls:0.95%
—
—
—
—
—
—
cases:3.19%
controls:0.70%
cases:3.45%
controls:2.05%
11
60
252
2563
21
25
242
2598
—
—
—
8
18
243
2564
8
48
224
2297
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
—
—
—
—
—
2.2e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.27%
cases:3.45%
controls:0.72%
—
—
—
—
—
6
7
245
2575
8
17
224
2328
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
4.7e-01
2.2e+00
—
—
—
9.6e-01
6.6e-01
cases:3.80%
controls:2.40%
cases:6.46%
controls:0.76%
—
—
—
—
—
—
cases:2.39%
controls:0.93%
cases:5.17%
controls:2.73%
10
63
253
2560
17
20
246
2603
—
—
—
6
24
245
2558
12
64
220
2281
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.55%
—
—
—
—
—
—
11
13
221
2332
Work problem
Z05 [2002001461]
-1.0e+50
—
—
—
—
—
2.2e+00
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.30%
0
5
263
2618
—
—
—
—
—
6
7
226
2338
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
1.3e+00
—
—
—
—
—
2.2e+00
cases:2.66%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:6.03%
controls:0.72%
7
19
256
2604
—
—
—
—
—
14
17
218
2328
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.60%
—
0
7
263
2616
—
—
—
—
11
14
221
2331
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
1.3e+00
2.1e+00
—
—
—
—
8.0e-01
cases:3.42%
controls:0.91%
cases:3.04%
controls:0.38%
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.58%
9
24
254
2599
8
10
255
2613
—
—
—
—
8
37
224
2308
Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
66885-5 [40769539]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.38%
—
—
—
—
—
—
7
9
225
2336
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.59%
controls:0.34%
—
—
—
—
—
—
6
8
226
2337
Protein [Mass/volume] in Urine
2888-6 [3037121]
—
2.0e+00
—
—
—
—
1.7e+00
—
—
cases:2.28%
controls:0.30%
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.38%
—
6
8
257
2615
—
—
—
—
5
9
227
2336
Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
3216-9 [3020427]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.47%
—
—
—
—
—
—
8
11
224
2334
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
9.8e-01
—
—
—
—
—
2.0e+00
cases:1.90%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.47%
5
19
258
2604
—
—
—
—
—
8
11
224
2334
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
1.1e+00
1.8e+00
—
—
—
—
2.0e+00
cases:2.66%
controls:0.88%
cases:2.28%
controls:0.38%
—
—
—
—
—
—
—
—
cases:5.17%
controls:0.72%
7
23
256
2600
6
10
257
2613
—
—
—
—
12
17
220
2328
verapamil; oral, parenteral
C08DA01 [21601767]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.43%
—
—
—
—
—
—
7
10
225
2335
Thrombin time
3243-3 [3036489]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.68%
—
—
—
—
—
—
11
16
221
2329
Gas panel - Arterial blood
24336-0 [3019060]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.64%
—
—
—
—
—
—
10
15
222
2330
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.64%
—
—
—
—
—
—
10
15
222
2330
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.1e-01
3.8e-01
1.9e+00
—
9.4e-01
3.8e-01
3.2e-01
cases:19.77%
controls:18.11%
cases:20.15%
controls:14.72%
cases:17.11%
controls:3.01%
—
—
cases:5.81%
controls:2.36%
cases:20.72%
controls:15.14%
cases:37.93%
controls:30.75%
52
475
211
2148
53
386
210
2237
45
79
218
2544
—
15
62
243
2561
52
391
199
2191
88
721
144
1624
Intravenous
ZX120 [2001311495]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.47%
—
—
—
—
—
—
7
11
225
2334
Intravenous general anesthesia
WX404 [2001310807]
2.3e-02
7.4e-01
—
—
—
—
1.9e+00
cases:3.04%
controls:2.97%
cases:1.90%
controls:0.91%
—
—
—
—
—
—
—
—
cases:5.60%
controls:0.90%
8
78
255
2545
5
24
258
2599
—
—
—
—
13
21
219
2324
nystatin; oral
A07AA02 [21600604]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.55%
—
—
—
—
—
—
8
13
224
2332
Syncope and collapse
R55 [45568141]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.72%
—
—
—
—
—
—
10
17
222
2328
Immunohistochemistry procedure
117617002 [4035726]
—
1.3e+00
—
—
—
—
1.8e+00
—
—
cases:1.90%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.81%
—
5
14
258
2609
—
—
—
—
11
19
221
2326
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.02%
controls:0.51%
—
—
—
—
—
—
7
12
225
2333
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
4.1e-01
1.8e+00
—
—
—
1.4e+00
5.6e-01
cases:4.18%
controls:2.82%
cases:7.98%
controls:1.45%
—
—
—
—
—
—
cases:3.59%
controls:0.93%
cases:5.60%
controls:3.28%
11
74
252
2549
21
38
242
2585
—
—
—
9
24
242
2558
13
77
219
2268
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.68%
—
—
—
—
—
—
9
16
223
2329
Gas panel - Capillary blood
24337-8 [3022313]
1.3e+00
—
—
—
—
—
1.8e+00
cases:2.66%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.68%
7
19
256
2604
—
—
—
—
—
9
16
223
2329
rofecoxib; oral
M01AH02 [21603993]
1.8e+00
—
—
—
—
—
—
cases:3.04%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
8
14
255
2609
—
—
—
—
—
—
Other specified counselling
Z71.8 [45581061]
1.8e-01
1.8e+00
—
—
-1.0e+50
3.2e-01
3.8e-01
cases:3.80%
controls:3.20%
cases:5.32%
controls:0.95%
—
—
—
—
cases:0.00%
controls:0.27%
cases:2.39%
controls:1.74%
cases:7.76%
controls:5.46%
10
84
253
2539
14
25
249
2598
—
—
0
7
258
2616
6
45
245
2537
18
128
214
2217
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.02%
—
—
—
—
—
—
13
24
219
2321
felodipine; oral
C08CA02 [21601748]
5.8e-01
1.1e+00
—
—
—
1.1e+00
1.7e+00
cases:2.28%
controls:1.30%
cases:2.28%
controls:0.80%
—
—
—
—
—
—
cases:2.79%
controls:0.97%
cases:6.90%
controls:1.28%
6
34
257
2589
6
21
257
2602
—
—
—
7
25
244
2557
16
30
216
2315
Otolaryngology
4 [38004449]
5.3e-01
5.7e-01
—
—
—
1.0e+00
6.8e-01
cases:16.35%
controls:10.29%
cases:6.84%
controls:4.00%
—
—
—
—
—
—
cases:8.37%
controls:3.18%
cases:17.24%
controls:9.51%
43
270
220
2353
18
105
245
2518
—
—
—
21
82
230
2500
40
223
192
2122
Pain localized to upper abdomen
R10.1 [45568111]
—
1.7e+00
—
—
—
—
6.2e-01
—
—
cases:3.04%
controls:0.57%
—
—
—
—
—
—
—
—
cases:3.88%
controls:2.13%
—
8
15
255
2608
—
—
—
—
9
50
223
2295
Asthma
R96 [2002000961]
1.7e+00
—
—
—
—
—
1.2e+00
cases:4.56%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:1.15%
12
23
251
2600
—
—
—
—
—
9
27
223
2318
Chronic apical periodontitis
K04.5 [45586691]
3.7e-01
1.2e+00
—
—
—
1.7e+00
6.8e-01
cases:4.18%
controls:2.94%
cases:2.66%
controls:0.80%
—
—
—
—
—
—
cases:3.59%
controls:0.70%
cases:7.33%
controls:3.84%
11
77
252
2546
7
21
256
2602
—
—
—
9
18
242
2564
17
90
215
2255
Bacterial pneumonia, unspecified
J15.9 [45557621]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.68%
—
—
—
—
—
—
8
16
224
2329
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.2e+00
—
—
—
—
—
1.6e+00
cases:3.04%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.15%
8
24
255
2599
—
—
—
—
—
13
27
219
2318
spironolactone; oral
C03DA01 [21601534]
1.2e+00
1.3e+00
—
—
—
1.6e+00
9.5e-01
cases:2.66%
controls:0.84%
cases:2.66%
controls:0.76%
—
—
—
—
—
—
cases:3.98%
controls:0.81%
cases:4.31%
controls:1.71%
7
22
256
2601
7
20
256
2603
—
—
—
10
21
241
2561
10
40
222
2305
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
1.3e+00
—
—
—
—
—
1.6e+00
cases:3.04%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:4.74%
controls:0.98%
8
22
255
2601
—
—
—
—
—
11
23
221
2322
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.1e+00
1.4e+00
—
—
—
2.2e+00
1.6e+00
cases:1.90%
controls:0.61%
cases:1.90%
controls:0.46%
—
—
—
—
—
—
cases:1.99%
controls:0.23%
cases:4.74%
controls:0.98%
5
16
258
2607
5
12
258
2611
—
—
—
5
6
246
2576
11
23
221
2322
Infectious Disease
44 [38004484]
1.3e+00
1.5e+00
—
—
—
1.3e+00
1.6e+00
cases:3.42%
controls:0.99%
cases:2.28%
controls:0.50%
—
—
—
—
—
—
cases:1.99%
controls:0.54%
cases:6.47%
controls:1.41%
9
26
254
2597
6
13
257
2610
—
—
—
5
14
246
2568
15
33
217
2312
Person consulting for explanation of investigation findings
Z71.2 [45552100]
3.6e-01
1.6e+00
—
—
—
1.1e+00
8.3e-01
cases:3.42%
controls:2.40%
cases:4.56%
controls:0.99%
—
—
—
—
—
—
cases:3.19%
controls:1.08%
cases:7.33%
controls:3.33%
9
63
254
2560
12
26
251
2597
—
—
—
8
28
243
2554
17
78
215
2267
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
8.8e-01
—
—
—
—
—
1.6e+00
cases:1.90%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.24%
5
21
258
2602
—
—
—
—
—
13
29
219
2316
pH of Capillary blood
2745-8 [3009343]
1.3e+00
—
—
—
—
—
1.5e+00
cases:3.04%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:5.17%
controls:1.15%
8
22
255
2601
—
—
—
—
—
12
27
220
2318
Cathetrisation of vein
TPH04 [2001309597]
6.0e-01
9.2e-01
—
—
—
1.2e+00
1.5e+00
cases:3.42%
controls:1.91%
cases:1.90%
controls:0.76%
—
—
—
—
—
—
cases:1.99%
controls:0.62%
cases:7.33%
controls:1.66%
9
50
254
2573
5
20
258
2603
—
—
—
5
16
246
2566
17
39
215
2306
codeine; oral
R05DA04 [21603399]
3.7e-01
1.5e+00
—
—
—
—
4.5e-01
cases:4.18%
controls:2.94%
cases:3.42%
controls:0.76%
—
—
—
—
—
—
—
—
cases:3.45%
controls:2.22%
11
77
252
2546
9
20
254
2603
—
—
—
—
8
52
224
2293
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.9e-01
5.7e-01
—
1.0e+50
—
1.5e+00
5.8e-01
cases:7.22%
controls:6.06%
cases:4.94%
controls:2.86%
—
—
cases:2.28%
controls:0.00%
—
—
cases:9.16%
controls:2.17%
cases:10.78%
controls:6.35%
19
159
244
2464
13
75
250
2548
—
6
0
257
2623
—
23
56
228
2526
25
149
207
2196
Fungus identified in Specimen by Culture
580-1 [3000494]
—
1.2e+00
—
—
—
1.5e+00
1.5e+00
—
—
cases:1.90%
controls:0.57%
—
—
—
—
—
—
cases:1.99%
controls:0.46%
cases:8.19%
controls:1.96%
—
5
15
258
2608
—
—
—
5
12
246
2570
19
46
213
2299
Monitoring the use of the aid
R5140 [2001310249]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.32%
—
—
—
—
—
—
13
31
219
2314
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
8.3e-01
—
—
1.0e+50
—
1.5e+00
—
—
cases:1.90%
controls:0.84%
—
—
—
—
cases:1.94%
controls:0.00%
—
—
cases:6.47%
controls:1.58%
—
5
22
258
2601
—
—
5
0
253
2623
—
15
37
217
2308
Acute upper respiratory infection, unspecified
J06.9 [45562437]
7.7e-01
6.2e-01
—
—
—
5.5e-01
6.8e-01
cases:13.31%
controls:6.63%
cases:5.32%
controls:2.94%
—
—
—
—
—
—
cases:5.98%
controls:3.52%
cases:21.55%
controls:12.20%
35
174
228
2449
14
77
249
2546
—
—
—
15
91
236
2491
50
286
182
2059
General anesthesia, balanced
WX408 [2001310808]
-2.6e-02
9.3e-01
—
—
—
—
1.4e+00
cases:3.42%
controls:3.51%
cases:2.28%
controls:0.91%
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.41%
9
92
254
2531
6
24
257
2599
—
—
—
—
13
33
219
2312
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.03%
controls:1.54%
—
—
—
—
—
—
14
36
218
2309
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
1.2e+00
—
1.0e+50
—
—
1.4e+00
—
—
cases:1.90%
controls:0.57%
—
—
cases:1.90%
controls:0.00%
—
—
—
—
cases:6.47%
controls:1.66%
—
5
15
258
2608
—
5
0
258
2623
—
—
15
39
217
2306
cetirizine; oral
R06AE07 [21603497]
6.4e-01
7.3e-01
—
—
—
7.5e-01
7.6e-01
cases:14.83%
controls:8.43%
cases:7.98%
controls:4.00%
—
—
—
—
—
—
cases:8.76%
controls:4.34%
cases:15.52%
controls:7.89%
39
221
224
2402
21
105
242
2518
—
—
—
22
112
229
2470
36
185
196
2160
Respiratory and circulatory monitoring
WX700 [2001310817]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:1.11%
—
—
—
—
—
—
10
26
222
2319
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
1.2e+00
—
1.0e+50
—
—
1.4e+00
—
—
cases:1.90%
controls:0.57%
—
—
cases:1.90%
controls:0.00%
—
—
—
—
cases:6.47%
controls:1.71%
—
5
15
258
2608
—
5
0
258
2623
—
—
15
40
217
2305
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
1.2e+00
—
1.0e+50
—
—
1.4e+00
—
—
cases:1.90%
controls:0.57%
—
—
cases:1.90%
controls:0.00%
—
—
—
—
cases:6.47%
controls:1.71%
—
5
15
258
2608
—
5
0
258
2623
—
—
15
40
217
2305
pH of Arterial blood
2744-1 [3019977]
—
1.2e+00
—
1.0e+50
—
—
1.4e+00
—
—
cases:1.90%
controls:0.57%
—
—
cases:1.90%
controls:0.00%
—
—
—
—
cases:6.47%
controls:1.71%
—
5
15
258
2608
—
5
0
258
2623
—
—
15
40
217
2305
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
5.4e-01
1.4e+00
—
—
—
—
9.3e-01
cases:3.42%
controls:2.02%
cases:3.80%
controls:0.99%
—
—
—
—
—
—
—
—
cases:6.03%
controls:2.47%
9
53
254
2570
10
26
253
2597
—
—
—
—
14
58
218
2287
cefalexin; oral
J01DB01 [21602870]
3.3e-01
7.4e-01
7.0e-01
—
7.2e-01
4.6e-01
6.3e-01
cases:34.60%
controls:27.64%
cases:15.59%
controls:8.08%
cases:1.90%
controls:0.95%
—
—
cases:1.94%
controls:0.95%
cases:12.35%
controls:8.13%
cases:37.93%
controls:24.56%
91
725
172
1898
41
212
222
2411
5
25
258
2598
—
5
25
253
2598
31
210
220
2372
88
576
144
1769
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
2.8e-01
1.4e+00
—
—
—
8.7e-01
7.3e-01
cases:4.94%
controls:3.77%
cases:6.46%
controls:1.75%
—
—
—
—
—
—
cases:3.98%
controls:1.70%
cases:10.78%
controls:5.50%
13
99
250
2524
17
46
246
2577
—
—
—
10
44
241
2538
25
129
207
2216
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.17%
controls:1.45%
—
—
—
—
—
—
12
34
220
2311
Gynaecological examination (general)(routine)
Z01.4 [45542395]
1.7e-01
—
—
—
—
—
1.3e+00
cases:1.90%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.58%
5
42
258
2581
—
—
—
—
—
13
37
219
2308
pregabalin; oral
N02BF02 [955152]
9.2e-02
5.9e-01
—
—
—
—
1.3e+00
cases:3.04%
controls:2.78%
cases:2.66%
controls:1.49%
—
—
—
—
—
—
—
—
cases:9.48%
controls:2.81%
8
73
255
2550
7
39
256
2584
—
—
—
—
22
66
210
2279
General medical examination
Z00.0 [45585791]
1.3e+00
1.5e+00
—
—
—
—
6.9e-01
cases:5.32%
controls:1.56%
cases:2.66%
controls:0.61%
—
—
—
—
—
—
—
—
cases:4.31%
controls:2.22%
14
41
249
2582
7
16
256
2607
—
—
—
—
10
52
222
2293
dexamethasone and antiinfectives
S03CA01 [21605206]
8.7e-01
1.4e+00
—
—
—
—
1.3e+00
cases:4.18%
controls:1.79%
cases:1.90%
controls:0.46%
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.66%
11
47
252
2576
5
12
258
2611
—
—
—
—
13
39
219
2306
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.2e+00
—
—
—
—
—
1.3e+00
cases:2.66%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:5.17%
controls:1.54%
7
22
256
2601
—
—
—
—
—
12
36
220
2309
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.3e-01
6.6e-01
4.0e-01
—
4.4e-01
5.8e-01
4.4e-01
cases:34.98%
controls:27.91%
cases:22.43%
controls:13.00%
cases:3.04%
controls:2.06%
—
—
cases:3.10%
controls:2.02%
cases:22.71%
controls:14.10%
cases:43.53%
controls:33.26%
92
732
171
1891
59
341
204
2282
8
54
255
2569
—
8
53
250
2570
57
364
194
2218
101
780
131
1565
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.0e-01
6.6e-01
—
—
1.5e+00
1.2e+00
6.8e-01
cases:11.03%
controls:6.98%
cases:5.32%
controls:2.82%
—
—
—
—
cases:1.94%
controls:0.46%
cases:7.97%
controls:2.44%
cases:12.50%
controls:6.74%
29
183
234
2440
14
74
249
2549
—
—
5
12
253
2611
20
63
231
2519
29
158
203
2187
ketoprofen; ointment
M02AA10 [21604046]
1.2e+00
—
—
—
—
—
7.6e-01
cases:5.32%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:1.02%
14
43
249
2580
—
—
—
—
—
5
24
227
2321
metronidazole; oral, rectal
P01AB01 [21604857]
4.9e-01
7.9e-01
—
—
—
1.2e+00
5.6e-01
cases:10.65%
controls:6.82%
cases:3.80%
controls:1.75%
—
—
—
—
—
—
cases:5.58%
controls:1.74%
cases:9.05%
controls:5.37%
28
179
235
2444
10
46
253
2577
—
—
—
14
45
237
2537
21
126
211
2219
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
3.6e-01
8.7e-01
—
—
—
4.9e-01
1.2e+00
cases:3.42%
controls:2.40%
cases:4.18%
controls:1.79%
—
—
—
—
—
—
cases:2.39%
controls:1.47%
cases:9.91%
controls:3.33%
9
63
254
2560
11
47
252
2576
—
—
—
6
38
245
2544
23
78
209
2267
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.60%
controls:1.83%
—
—
—
—
—
—
13
43
219
2302
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
1.7e+00
—
—
—
1.7e+00
1.2e+00
—
—
cases:1.90%
controls:0.34%
—
—
—
—
—
—
cases:2.39%
controls:0.43%
cases:6.47%
controls:2.13%
—
5
9
258
2614
—
—
—
6
11
245
2571
15
50
217
2295
Stomach Pathology biopsy report
66114-0 [40768797]
2.9e-01
—
—
—
—
1.8e+00
1.1e+00
cases:2.28%
controls:1.72%
—
—
—
—
—
—
—
—
cases:1.99%
controls:0.35%
cases:7.33%
controls:2.47%
6
45
257
2578
—
—
—
—
5
9
246
2573
17
58
215
2287
beclometasone; inhalant
R03BA01 [21603284]
1.1e+00
1.3e+00
—
—
—
1.4e+00
1.0e+00
cases:6.46%
controls:2.17%
cases:3.80%
controls:1.07%
—
—
—
—
—
—
cases:2.79%
controls:0.74%
cases:3.88%
controls:1.41%
17
57
246
2566
10
28
253
2595
—
—
—
7
19
244
2563
9
33
223
2312
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
6.3e-01
2.0e-01
—
—
—
1.2e+00
1.1e+00
cases:6.84%
controls:3.77%
cases:2.28%
controls:1.87%
—
—
—
—
—
—
cases:3.59%
controls:1.16%
cases:13.36%
controls:4.73%
18
99
245
2524
6
49
257
2574
—
—
—
9
30
242
2552
31
111
201
2234
Emergency Room and Inpatient Visit
ERIP [262]
1.1e+00
1.1e+00
—
1.0e+50
—
8.9e-01
5.6e-01
cases:6.08%
controls:2.06%
cases:4.56%
controls:1.52%
—
—
cases:2.28%
controls:0.00%
—
—
cases:3.59%
controls:1.51%
cases:9.91%
controls:5.93%
16
54
247
2569
12
40
251
2583
—
6
0
257
2623
—
9
39
242
2543
23
139
209
2206
betamethasone
A07EA04 [21600656]
4.3e-01
5.4e-01
-1.0e+50
—
-1.0e+50
1.1e+00
1.7e-01
cases:9.13%
controls:6.14%
cases:4.18%
controls:2.48%
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.23%
cases:5.18%
controls:1.82%
cases:8.62%
controls:7.38%
24
161
239
2462
11
65
252
2558
0
6
263
2617
—
0
6
258
2617
13
47
238
2535
20
173
212
2172
betamethasone
S02BA07 [21605169]
4.3e-01
5.4e-01
-1.0e+50
—
-1.0e+50
1.1e+00
1.7e-01
cases:9.13%
controls:6.14%
cases:4.18%
controls:2.48%
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.23%
cases:5.18%
controls:1.82%
cases:8.62%
controls:7.38%
24
161
239
2462
11
65
252
2558
0
6
263
2617
—
0
6
258
2617
13
47
238
2535
20
173
212
2172
betamethasone
C05AA05 [21601610]
4.3e-01
5.4e-01
-1.0e+50
—
-1.0e+50
1.1e+00
1.7e-01
cases:9.13%
controls:6.14%
cases:4.18%
controls:2.48%
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.23%
cases:5.18%
controls:1.82%
cases:8.62%
controls:7.38%
24
161
239
2462
11
65
252
2558
0
6
263
2617
—
0
6
258
2617
13
47
238
2535
20
173
212
2172

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
174
727
5.03
36.55
13.1
6.4
—
—
—
0
0
47
70
7.94
31.26
1.5
1.3
—
—
—
0
0
67
144
5.88
31.22
4.1
2.7
7.42
7.42
ph
0.01
60
121
47
71
7.83
30.86
1.5
1.3
169.09
111.43
titre
—
11
7
33
32
11.63
30.40
5.2
2.4
—
—
—
0
0
215
1169
5.38
29.49
14.6
7.3
13.51
11.78
umol/l
0.76
210
1113
40
54
8.54
28.83
2.5
1.8
24.54
25.37
mmol/l
0.43
40
54
184
941
4.10
26.17
12.2
10.2
1.17
1.17
inr
0.01
164
772
211
1210
4.60
24.89
14.9
6.6
0.20
0.19
e9/l
0.29
200
1078
89
287
4.16
24.78
2.1
2.2
23.43
24.48
%
0.23
82
273
28
30
10.31
23.95
2.3
2.9
—
—
—
0
0
91
308
3.97
23.53
2.2
2.1
2.34
2.37
g/l
0.16
86
288
207
1197
4.29
23.48
14.1
6.5
1.85
1.98
e9/l
0.69
195
1071
204
1170
4.19
23.38
14.2
6.5
0.61
0.56
e9/l
3.08
193
1012
204
1174
4.16
23.16
14.2
6.5
0.05
0.04
e9/l
2.73
193
1016
176
925
3.67
22.86
10.3
4.6
36.35
36.10
g/l
0.21
170
874
30
11
30.51
22.81
3.9
1.5
38.33
68.98
ug/l
1.48
30
11
76
242
4.00
21.21
8.1
5.4
1.01
1.04
mmol/l
0.60
69
224
127
565
3.39
21.20
4.3
3.2
896.49
1018.22
ng/l
0.19
113
481
184
1033
3.53
20.71
15.0
6.8
1.21
1.21
mmol/l
0.89
167
887
27
35
8.47
19.92
4.9
1.7
—
—
—
0
0
27
35
8.47
19.92
4.9
1.7
—
—
—
0
0
27
35
8.47
19.92
4.9
1.7
—
—
—
0
0
27
35
8.47
19.92
4.9
1.7
—
—
—
0
0
47
109
5.02
19.65
4.7
2.7
—
—
—
0
0
91
345
3.49
19.39
1.7
1.4
350.77
552.21
titre
0.99
26
77
73
241
3.80
19.17
4.0
1.5
—
—
—
0
0
69
221
3.87
18.92
14.4
9.4
1.70
1.01
mmol/l
0.84
61
184
33
57
6.47
18.87
2.9
3.1
8.23
8.34
kpa
0.11
33
57
208
1314
3.67
18.25
16.2
10.4
3.91
3.81
e9/l
0.33
195
1153
25
35
7.78
17.26
2.6
2.0
90.29
88.52
%
0.50
25
35
164
926
3.01
16.97
13.7
6.3
1.21
1.21
mmol/l
0.30
154
852
67
228
3.59
16.63
14.8
9.2
7.42
7.41
ph
0.56
43
132
45
116
4.47
16.43
3.1
7.8
—
—
—
0
0
111
517
2.97
16.22
2.5
1.4
2.62
2.39
g/l
0.58
98
319
25
38
7.16
16.05
1.8
1.7
137.72
132.44
g/l
0.35
18
32
25
41
6.63
14.95
2.0
1.4
0.79
0.71
g/l
0.13
17
35
18
5
38.42
14.63
3.7
2.6
—
—
—
0
0
110
548
2.72
13.70
10.9
3.9
90.78
92.55
%
0.31
105
540
73
293
3.06
13.61
1.5
1.7
—
—
—
0
0
76
320
2.92
12.95
5.6
3.0
0.98
1.46
e6/l
0.34
52
161
55
193
3.33
12.79
7.1
6.3
0.06
0.07
%
0.04
17
44
127
698
2.57
12.74
3.6
2.5
62.81
71.85
u/l
0.42
119
649
70
284
2.99
12.73
19.9
6.3
104.43
104.35
mmol/l
0.05
70
284
54
188
3.35
12.72
6.8
5.8
0.00
0.16
%
1.71
17
51
71
291
2.96
12.68
1.5
1.3
—
—
—
0
0
70
285
2.98
12.64
4.0
3.1
7.46
7.95
umol/l
0.12
62
251
17
7
25.81
12.63
4.4
1.4
—
—
—
0
0
55
201
3.19
11.93
6.7
5.5
0.50
0.88
%
0.82
20
65
99
499
2.57
11.71
2.7
1.6
1.35
1.37
mg/l
0.02
79
379
53
193
3.18
11.54
5.5
5.5
0.38
0.36
%
0.07
17
56
188
1279
2.60
11.48
13.7
4.7
6.50
6.46
mmol/l
0.09
179
1205
26
57
4.95
11.45
1.2
1.4
314.77
294.25
ug/g
0.13
13
33
73
320
2.77
11.39
4.0
2.1
—
—
—
0
0
19
15
13.54
11.33
1.8
1.1
—
—
—
0
0
107
567
2.48
11.31
9.1
2.6
367.78
336.57
umol/l
2.17
96
505
105
555
2.47
11.12
5.4
4.6
—
—
—
0
0
152
960
2.36
10.62
4.6
2.3
77.18
75.23
nmol/l
0.37
143
862
84
408
2.55
10.58
1.6
1.7
—
—
—
0
0
26
61
4.62
10.56
1.1
1.2
386.47
238.50
u/ml
0.71
17
40
65
281
2.74
10.33
4.7
1.5
—
—
—
0
0
121
701
2.33
10.24
7.8
2.9
37.81
123.90
e6/l
0.45
96
543
31
87
3.90
9.99
1.1
1.3
—
—
—
0
0
217
1633
2.79
9.93
6.3
3.1
63.96
46.32
u/l
2.42
212
1548
14
7
21.01
9.91
1.0
1.1
—
—
—
0
0
14
7
21.01
9.91
1.0
1.0
—
—
—
0
0
110
620
2.32
9.84
8.1
3.8
7.40
7.40
ph
0.00
84
448
159
1048
2.29
9.73
22.4
10.4
0.00
0.00
e9/l
0.56
142
850
22
32
7.39
9.54
4.9
1.8
—
—
—
0
0
206
1529
2.54
9.40
8.2
3.9
—
2.91
—
0
5
143
913
2.22
9.32
4.3
3.1
6.32
6.23
ph
0.38
80
541
105
593
2.27
9.23
8.2
2.9
0.12
0.40
e6/l
2.77
84
436
64
290
2.59
9.18
4.5
2.9
4.24
5.23
e9/l
0.57
55
265
131
813
2.20
9.10
9.1
3.4
53.44
74.77
e6/l
0.27
98
570
15
12
13.16
8.98
1.1
1.1
—
—
—
0
0
32
99
3.54
8.95
1.8
1.5
0.13
0.29
mg/l
—
8
40
15
13
12.15
8.68
1.1
1.1
—
—
—
0
0
18
23
8.31
8.51
1.6
1.3
—
—
—
0
0
97
553
2.19
8.15
9.1
5.4
—
—
—
0
0
22
56
4.19
8.06
1.4
1.3
161.33
153.38
au/ml
—
6
17
20
33
6.46
8.02
1.3
1.2
—
—
—
0
0
94
536
2.17
7.84
2.9
2.0
3.27
2.97
mg/l
0.45
83
467
167
1183
2.11
7.79
5.7
3.4
34.29
0.00
estimate
0.49
51
257
45
185
2.72
7.76
4.5
3.7
7.38
7.35
ph
0.89
34
129
19
31
6.51
7.70
1.2
1.3
—
—
—
0
0
47
199
2.65
7.65
1.5
1.6
—
—
—
0
0
16
21
8.03
7.50
1.5
1.3
—
—
—
0
0
164
1166
2.06
7.42
5.7
3.4
0.00
0.00
estimate
-0.00
49
254
16
22
7.66
7.30
1.5
1.3
6.56
5.97
g/l
—
10
17
16
22
7.66
7.30
1.5
1.3
2.30
3.01
g/l
—
10
17
16
22
7.66
7.30
1.5
1.3
0.33
0.32
g/l
—
10
17
166
1193
2.04
7.20
5.7
3.4
0.00
1.23
estimate
0.50
51
246
189
1426
2.12
7.15
8.3
3.9
53.71
45.95
e6/l
—
7
22
152
1062
2.01
7.10
3.5
2.7
157.94
125.43
ug/l
0.90
145
996
108
670
2.03
7.06
3.8
3.6
7.87
5.24
mg/mmol
0.30
72
406
39
158
2.72
6.90
2.0
3.4
71.36
71.60
e9/l
0.01
29
124
18
32
5.95
6.89
1.3
1.3
2.50
4.24
u/ml
—
8
17
59
293
2.30
6.79
3.5
2.3
236.05
97.42
ug/g
2.17
43
237
17
32
5.60
6.27
1.9
1.7
17.55
16.99
%
0.27
17
32
17
32
5.60
6.27
3.6
4.3
3.40
4.64
e9/l
1.37
17
32
19
53
3.78
6.16
3.5
3.5
51.96
56.87
%
0.67
19
53
103
657
1.93
6.02
3.4
3.1
42.47
33.88
mg/l
0.22
70
412
10
9
11.49
5.84
3.4
1.8
18.10
16.80
%
—
10
9
10
9
11.49
5.84
2.1
2.0
—
—
—
0
0
53
272
2.18
5.58
1.6
1.3
—
—
—
0
0
119
813
1.84
5.50
5.5
3.0
42.66
111.98
ng/l
0.44
100
534
12
17
7.34
5.50
1.7
1.9
—
—
—
0
0
8
5
16.42
5.44
3.1
3.4
0.60
0.61
mmol/l
—
8
5
91
579
1.87
5.23
3.7
2.4
—
—
—
0
0
38
176
2.35
5.08
1.7
1.5
—
—
—
0
0
62
353
1.99
4.93
6.3
3.5
1008.69
401.25
ng/l
0.98
51
248
10
13
7.94
4.89
2.1
1.8
3218.00
28537.13
e6/l
—
5
8
21
73
3.04
4.89
2.2
3.6
264.09
334.72
mg/l
0.28
11
32
105
719
1.76
4.63
3.4
2.9
7.22
8.16
mmol/l
1.48
95
611
76
476
1.84
4.50
1.8
2.1
—
—
—
0
0
25
103
2.58
4.28
4.7
3.7
37.02
36.90
°c
1.90
25
103
99
680
1.73
4.25
11.2
6.3
—
—
—
0
0
10
17
6.07
4.17
1.1
1.1
—
—
—
0
0
37
185
2.16
4.13
6.0
3.1
—
—
—
0
0
102
711
1.70
4.13
6.9
3.2
2.31
2.36
mmol/l
2.31
95
648
14
42
3.46
4.10
1.1
1.1
—
—
—
0
0
35
174
2.16
3.96
24.7
8.4
—
—
—
0
0
103
729
1.67
3.89
3.5
2.4
—
—
—
0
0
13
33
4.09
3.85
1.5
1.2
—
—
—
0
0
47
264
1.95
3.84
1.9
1.7
—
—
—
0
0
84
565
1.71
3.83
1.3
1.3
0.61
1.32
u/ml
1.10
25
169
72
465
1.75
3.78
1.4
1.4
19.36
31.12
iu/ml
0.78
21
137
203
1725
1.75
3.65
5.4
4.1
14.77
14.74
pmol/l
0.05
189
1576
40
216
2.00
3.65
3.1
5.3
4.26
57.58
ug/l
0.81
32
176
13
35
3.85
3.64
1.5
4.7
—
—
—
0
0
62
390
1.77
3.55
1.8
1.7
470.33
441.01
pmol/l
0.35
52
334
6
6
10.19
3.51
1.8
1.3
—
—
—
0
0
135
1044
1.60
3.47
4.2
2.9
—
—
estimate
—
0
0
35
184
2.04
3.44
4.2
2.0
0.17
0.18
e6/l
0.02
35
173
9
18
5.13
3.40
1.7
2.2
—
—
—
0
0
7
10
7.15
3.38
2.0
1.5
—
—
—
0
0
24
109
2.32
3.37
2.5
2.2
21.30
4.26
iu/ml
—
6
32
13
43
3.13
3.30
1.2
1.1
—
—
—
0
0
10
25
4.11
3.12
5.4
1.7
11.70
10.80
mmol/l
—
10
25
35
192
1.95
3.07
6.1
3.5
5.82
5.77
kpa
0.10
35
187
94
683
1.58
3.06
5.3
3.5
0.00
0.00
estimate
-0.00
49
243
118
914
1.52
2.84
2.3
1.9
93.95
99.60
pmol/l
0.70
72
463
36
205
1.87
2.83
1.9
2.0
0.00
0.06
estimate
—
7
52
247
2278
2.18
2.82
33.1
13.5
18.21
22.91
mg/l
2.66
232
1815
10
28
3.67
2.81
2.3
2.2
—
—
—
0
0
91
668
1.55
2.79
6.1
2.8
0.00
0.12
estimate
0.52
44
209
5
6
8.46
2.76
2.0
3.7
—
—
—
0
0
7
14
5.10
2.74
1.6
1.6
10.51
11.06
umol/l
—
7
14
12
43
2.88
2.68
1.1
1.1
—
22.91
—
0
13
33
187
1.87
2.64
6.2
3.5
2.13
2.21
mmol/l
0.04
28
159
6
11
5.55
2.55
4.0
1.4
7.43
6.48
mmol/l
—
6
11
42
260
1.73
2.52
1.4
2.0
—
—
—
0
0
11
37
3.06
2.52
1.5
1.9
5.08
6.20
pmol/l
0.77
11
37
25
132
1.99
2.45
2.7
2.1
—
—
—
0
0
9
27
3.41
2.41
1.2
2.9
2.62
2.50
nmol/l
—
9
27
8
22
3.72
2.38
1.1
1.2
—
—
—
0
0
17
78
2.26
2.36
3.6
2.7
—
—
—
0
0
227
2066
1.67
2.32
6.5
4.9
1.80
1.89
mu/l
0.53
212
1906
8
23
3.55
2.29
1.3
1.1
91.05
89.86
%
—
8
23
9
29
3.18
2.24
1.3
1.4
1.51
1.53
mmol/l
—
9
29
35
213
1.74
2.24
3.5
2.9
29.44
33.93
u/l
0.40
27
185
79
593
1.47
2.11
2.1
1.5
18.76
20.14
nmol/l
0.40
69
495
25
140
1.87
2.09
33.0
8.8
93.97
93.74
%
0.10
25
140
5
10
5.07
2.08
1.0
1.0
—
—
—
0
0
5
10
5.07
2.08
1.0
2.0
—
—
—
0
0
7
20
3.57
2.07
1.0
1.3
123.43
112.40
pmol/l
—
7
20
20
104
2.00
2.06
1.5
1.2
—
2.67
—
0
7
47
317
1.59
2.05
1.9
1.6
1154.37
1232.48
nmol/l
0.26
38
246
29
172
1.77
2.03
5.2
2.9
4.28
4.72
kpa
0.94
29
167
7
21
3.39
1.98
1.1
1.1
—
—
—
0
0
233
2157
1.65
1.94
5.4
4.0
1.27
1.28
mmol/l
0.09
225
2005
6
16
3.81
1.94
3.0
2.3
107.50
105.56
mmol/l
—
6
16
6
16
3.81
1.94
3.0
2.3
4.22
4.11
mmol/l
—
6
16
6
16
3.81
1.94
3.0
2.3
1.23
1.20
mmol/l
—
6
16
110
890
1.40
1.93
2.9
2.0
—
—
—
0
0
7
22
3.24
1.89
2.0
2.0
—
—
—
0
0
18
95
1.96
1.80
1.2
1.4
215.30
256.31
miu/ml
—
5
45
58
422
1.48
1.79
1.5
1.3
11.01
10.81
u/ml
0.01
21
183
6
18
3.38
1.75
5.3
2.6
0.67
0.94
index
—
6
18
18
96
1.94
1.75
1.7
1.7
—
—
—
0
0
5
13
3.90
1.72
1.0
3.8
65.80
169.23
nmol/l
—
5
13
30
190
1.65
1.69
6.8
3.5
7.38
7.39
ph
0.17
22
109
10
42
2.43
1.63
7.2
3.5
—
—
—
0
0
253
2416
1.97
1.60
23.5
11.4
33.26
27.11
u/l
5.96
253
2358
248
2356
1.78
1.57
23.0
12.0
—
—
—
0
0
13
64
2.08
1.57
3.5
3.3
2.29
2.48
index
—
7
40
88
708
1.36
1.54
1.8
1.5
—
—
—
0
0
110
916
1.34
1.54
5.9
3.2
0.07
0.01
estimate
0.37
41
218
210
1935
1.41
1.46
35.0
17.0
13.66
13.53
%
0.71
210
1911
230
2155
1.50
1.45
6.0
4.7
5.78
5.85
mmol/l
0.43
211
1989
18
103
1.80
1.45
4.6
2.3
0.95
1.49
%
2.14
18
103
240
2270
1.59
1.43
6.5
4.7
4.66
4.71
mmol/l
0.27
232
2132
42
301
1.47
1.41
1.3
1.3
—
—
—
0
0
18
104
1.78
1.41
4.6
2.3
0.57
0.62
%
0.34
18
104
113
958
1.31
1.36
2.3
1.8
1.30
1.34
mmol/l
0.26
94
817
5
17
2.98
1.36
1.4
1.1
122.80
31.25
mg/l
—
5
12
0
39
0.00
1.35
0.0
3.8
—
40.41
—
0
39
174
1568
1.32
1.32
7.8
3.8
—
0.00
—
0
5
16
92
1.79
1.28
2.7
2.1
—
—
—
0
0
5
19
2.66
1.22
2.0
1.9
16.80
35.46
mg/l
—
5
13
22
141
1.61
1.21
1.2
1.2
—
—
—
0
0
24
158
1.57
1.19
1.2
1.4
336.80
124.68
u/ml
—
9
68
238
2263
1.49
1.19
6.4
4.6
1.49
1.46
mmol/l
0.39
230
2114
5
20
2.53
1.15
1.4
1.6
13.40
17.51
ug/l
—
5
20
14
81
1.77
1.11
2.9
1.8
13021.40
6283.40
u/l
—
5
29
5
23
2.20
0.98
1.0
1.0
—
—
—
0
0
5
23
2.20
0.98
1.2
1.2
—
—
—
0
0
224
2132
1.32
0.89
8.0
5.4
38.81
38.16
mmol/mol
0.61
213
2006
0
27
0.00
0.78
0.0
1.2
—
178.25
—
0
27
238
2294
1.36
0.77
6.9
5.3
2.65
2.79
mmol/l
1.85
231
2147
25
185
1.39
0.75
1.4
1.2
—
—
—
0
0
7
40
1.77
0.72
4.1
2.6
3.71
163.89
ug/min
—
7
18
5
26
1.94
0.71
1.2
1.5
—
—
—
0
0
5
26
1.94
0.71
1.6
1.7
15.00
34.80
ng/l
—
5
26
16
112
1.46
0.65
5.1
4.0
24.76
24.46
mmol/l
0.14
16
112
6
102
0.58
0.63
1.3
1.5
—
—
—
0
0
6
104
0.57
0.63
1.3
1.5
—
—
—
0
0
6
104
0.57
0.63
1.3
1.5
—
—
—
0
0
6
104
0.57
0.63
1.3
1.5
—
—
—
0
0
17
123
1.41
0.59
1.1
1.2
—
—
—
0
0
13
89
1.48
0.59
1.7
1.3
—
—
—
0
0
255
2500
1.48
0.57
43.6
20.8
91.56
90.74
fl
2.12
255
2475
5
89
0.55
0.57
2.6
1.3
30.36
22.87
iu/l
—
5
72
255
2501
1.47
0.56
43.5
20.8
30.39
30.29
pg
0.41
255
2475
255
2501
1.47
0.56
46.5
21.2
40.64
40.95
%
0.37
255
2475
6
37
1.64
0.56
1.3
1.1
—
—
—
0
0
6
96
0.62
0.53
1.3
1.6
—
—
—
0
0
255
2503
1.45
0.53
44.1
21.0
136.03
137.49
g/l
0.75
255
2477
7
45
1.57
0.49
1.0
1.0
—
—
—
0
0
7
45
1.57
0.49
1.0
1.0
—
—
—
0
0
7
49
1.44
0.46
1.1
1.4
—
—
—
0
0
5
33
1.52
0.41
1.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
9.4
—
0.68
—
0
16
254
2500
1.35
0.41
43.9
20.9
246.89
248.73
e9/l
0.17
254
2461
5
34
1.48
0.40
1.6
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
270.91
—
0
11
9
67
1.36
0.38
1.2
1.2
—
—
—
0
0
105
978
1.12
0.38
3.8
2.9
—
—
—
0
0
6
44
1.37
0.34
1.7
1.6
—
—
—
0
0
57
515
1.14
0.33
4.1
3.5
1.02
1.02
kg/l
0.55
45
344
7
98
0.71
0.31
1.0
1.1
1.76
1.52
g/l
—
7
98
19
157
1.23
0.30
1.9
3.1
—
—
—
0
0
86
804
1.10
0.28
4.4
5.2
1.74
2.57
ug/l
0.75
77
732
23
199
1.17
0.24
2.0
2.2
5.94
6.10
ph
0.50
16
131
5
38
1.32
0.23
3.2
3.6
68.66
66.30
%
—
5
38
5
38
1.32
0.23
3.2
2.2
67.80
67.26
%
—
5
38
5
41
1.22
0.22
1.2
1.5
—
—
—
0
0
19
219
0.86
0.21
1.8
1.8
3.32
3.49
mmol/l
0.20
13
174
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
0.00
—
0
12
0
13
0.00
0.21
0.0
4.0
—
—
—
0
0
0
14
0.00
0.20
0.0
16.9
—
866.21
—
0
14
0
14
0.00
0.20
0.0
3.8
—
—
—
0
0
12
100
1.21
0.18
1.9
1.1
0.85
0.92
g/l
0.39
12
100
200
1964
1.07
0.16
32.7
17.6
333.05
333.15
g/l
0.05
200
1955
15
130
1.16
0.16
1.1
1.1
—
—
—
0
0
9
108
0.83
0.13
2.1
1.9
—
—
—
0
0
49
512
0.95
0.09
2.1
3.2
0.65
0.72
ug/l
0.34
27
310
26
278
0.93
0.09
1.2
1.5
—
—
—
0
0
10
106
0.94
0.01
1.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
96.00
—
0
9
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
54
0.92
-0.00
1.2
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
57.80
—
0
5
0
6
0.00
-0.00
0.0
2.0
—
31.33
—
0
6
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
5
56
0.89
-0.00
1.4
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
71.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
16.50
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint E4_PLASMAPROT and mortality.

Females

Parameter HR [95% CI] p-value
E4_PLASMAPROT 2.638 [1.89, 3.68] < 0.001
Birth year 0.993 [0.98, 1.0] 0.116

During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 555 females with E4_PLASMAPROT died.

Males

Parameter HR [95% CI] p-value
E4_PLASMAPROT 3.193 [2.5, 4.09] < 0.001
Birth year 0.985 [0.98, 0.99] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 153 out of 681 males with E4_PLASMAPROT died.

Mortality risk

Mortality risk for people of age

years, who have E4_PLASMAPROT.

N-year risk Females Males
1 0.2% 0.625%
5 1.247% 3.59%
10 3.249% 8.999%
15 6.513% 16.458%
20 11.882% 26.107%

Relationships between endpoints

↥

Index endpoint: E4_PLASMAPROT – Disorders of plasma-protein metabolism, not elsewhere classified

GWS hits: 8

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data